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The present study utilised a candidate 
gene approach to identify gene vari-
ants associated with type 2 diabetes, 
obesity and related traits in individu-
als with impaired glucose tolerance. 
The candidate genes included in the 
present study, ADRA2B, ADIPOQ, 
ADIPOR1 and ADIPOR2, were select-
ed based on biological plausibility and 
the previous literature. The results of 
this thesis suggest that genetic differ-
ences in susceptibility to obesity and 
its comorbidities may exist. Moreover, 
individuals with different genotypes 
may respond differently to beneficial 
lifestyle changes.
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ABSTRACT:  
Obesity is a major risk factor for type 2 diabetes (T2DM), and both conditions are increasing 
rapidly worldwide. Excess adiposity is largely explained by lifestyle related factors, but 
genetic factors also contribute to an individuals’s susceptibility to gain weight or develop 
T2DM.  
Two entities can be separated in the pathophysiology of T2DM: 1) the compromised 
response of target tissues to insulin, namely insulin resistance, and 2) the failure of 
pancreatic beta cells to respond to increased requirement for insulin secretion. The majority 
of  currently  known  susceptibility  genes  for  T2DM  are  involved  in  beta  cell  function,  
whereas excess adiposity is a major determinant of insulin resistance. 
The aim of the present study was to examine the associations between common genetic 
variants in biologically plausible candidate genes and traits relating to obesity and T2DM in 
individuals with impaired glucose tolerance (IGT) who were participating in a randomised 
lifestyle intervention study, the Finnish Diabetes Prevention Study (DPS). The candidate 
genes were selected based on their known functions in metabolic pathways and the 
variants were selected based on previous literature and the haplotype structure of the 
human genome.  
The functional insertion/deletion variant 12Glu9 within the ADRA2B gene, encoding 
2B-adrenergic receptor, was associated with acute insulin secretion measured in a 
subpopulation of the DPS, and with the risk of converting from IGT to T2DM particularly 
in individuals with central obesity.  
Adiponectin is a regulatory molecule secreted by adipose tissue with insulin-sensitising, 
anti-atherogenic and anti-inflammatory effects. Common single nucleotide polymorphisms 
(SNPs) within the ADIPOQ gene, encoding adiponectin, were associated with serum 
adiponectin levels, the risk of T2DM and obesity related traits. Common SNPs in the gene 
encoding adiponectin receptor 1, ADIPOR1, were associated with various measures of body 
size  in  both  men  and  women.  In  addition,  differences  in  insulin  levels  according  to  
ADIPOR1 SNPs were seen, particularly in men. Variants in the gene encoding adiponectin 
receptor 2, ADIPOR2,  were  associated  with  the  risk  of  cardiovascular  event,  and  this  
finding was supported by tissue and allele specific differences seen in the mRNA 
expression levels.  
In summary, these studies suggest that genetic differences in susceptibility to obesity 
and  its  comorbidities  exist  in  individuals  with  an  increased  risk  of  T2DM.  An  interactive  
effect was seen between ADRA2B and lifestyle, whereas the effects of the adiponectin 
pathway variants were not modified by lifestyle. The results of these studies partly support 
the findings of earlier candidate gene studies, but also reveal novel associations.  
National Library of Medical Classification: QZ 50, WK 810, WK 820, GN 66 
Medical Subject Headings: Diabetes Mellitus, Type 2; Genes; Polymorphism, Single Nucleotide; Obesity; Body 
Size; Insulin; Adipose Tissue, Adiponectin  
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TIIVISTELMÄ 
Lihavuus on yleistynyt maailmanlaajuisesti viime vuosikymmeninä. Yleistymistä selittävät 
muutokset ruokavaliossa ja fyysisessä aktiivisuudessa, mutta myös perinnöllisillä tekijöillä 
on merkitystä. Lihavuudessa rasvakudoksen toiminta on häiriintynyt ja riski sairastua 
tyypin 2 diabetekseen sekä sydän- ja verisuonitauteihin on suurentunut. Rasvakudos toimii 
energiavarastona ja osallistuu monien elimistön toimintojen säätelyyn erittämiensä 
adipokiinien välityksellä. Adiponektiini on adipokiini, jonka pitoisuus verenkierrossa on 
vähentynyt lihavuudessa ja tyypin 2 diabeteksessa. Sillä on sokeriaineenvaihdunnan 
kannalta edullisia sekä sydän- ja verisuonitaudeilta suojaavia vaikutuksia. 
Tyypin 2 diabeteksen taustalla voidaan erottaa kaksi mekanismia, joiden häiriintyminen 
johtaa veren sokeritasojen nousuun: 1) insuliinin eritys haiman beta-soluista sekä 2) 
kohdekudosten herkkyys insuliinille on heikentynyt. Useimmat tähän mennessä 
tunnistetut tyypin 2 diabetekselle altistavat geenit liittyvät beta-solujen toimintaan, kun 
taas insuliiniherkkyys näyttäisi kytkeytyvän kiinteästi lihavuuteen.  
Tämän työn tarkoituksena oli selvittää eräiden kandidaattigeenien merkitystä 
lihavuuden ja tyypin 2 diabeteksen taustalla yksilöillä, joilla on heikentynyt glukoosinsieto 
ja näin ollen suurentunut riski sairastua tyypin 2 diabetekseen. 
ADRA2B-geenin toiminnallinen polymorfia, 12Glu9, oli yhteydessä ensivaiheen 
insuliinin eritykseen ja sitä kautta riskiin sairastua tyypin 2 diabetekseen. Glu9-alleelia 
kantavilla henkilöillä insuliinin eritys oli madaltunut ja tyypin 2 diabeteksen riski 
suurentunut. Elämäntapamuutokset näyttivät ehkäisevän riskialleelin kantajien 
sairastumista, kun taas vyötärölihavuus lisäsi entisestään riskialleelin kantajien 
sairastumisriskiä.  
Adiponektiinia koodaavan ADIPOQ-geenin useilla varianteilla havaittiin yhteys 
lihavuuteen ja tyypin 2 diabetekseen liittyviin muuttujiin sekä seerumin 
adiponektiinipitoisuuteen. Adiponektiinireseptoria 1 koodaavan ADIPOR1-geenin 
sekvenssimuunnokset olivat yhteydessä kehon kokoon ja koostumukseen sekä 
insuliinitasoihin. Adiponektiinireseptoria 2 koodaavan ADIPOR2-geenin variaatiot 
vaikuttavat riskiin sairastua sydän- ja verisuonitauteihin. Lisäksi ADIPOR2-geenin
ilmenemisessä havaittiin eroja yksitumaisissa valkosoluissa.  
Nämä tulokset osoittavat, että geneettiset tekijät saattavat vaikuttaa yksilöllisiin eroihin 
alttiudessa lihoa ja sairastua lihavuuden liitännäissairauksiin.  
Luokitus: QZ 50, WK 810, WK 820, GN 66 
Yleinen Suomalainen asiasanasto: aikuistyypin diabetes, rasvakudokset, geenitutkimus, painoindeksi, 
ylipaino, adiponektiini;  
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1 Introduction 
This series of studies examined the role of four candidate genes in obesity, type 2 diabetes 
(T2DM) and related phenotypes. The following literature review provides insight into the 
genetics of these complex phenotypes and also focuses on the functions of the candidate gene 
products.  
Complex diseases and quantitative traits, such as T2DM and obesity, are caused by a 
combination of multiple environmental and genetic factors, and their interactions. Although 
recent changes in human diet and lifestyle explain the rapid increase in the prevalence of 
obesity and its co-morbidities, these traits also have a strong genetic component as suggested by 
their aggregation in families and different prevalence rates in different ethnic groups. 
Moreover, the heritability estimates are high, ranging from 40 to 70% for obesity and from 25 to 
75% for T2DM.
The  first  draft  of  human  genome  was  finished  in  2001.  A  more  complete  picture  of  the  
genome and genetic variation among humans is emerging as more individuals are being 
sequenced and genotyped. Our genome contains approximately three billion base pairs and 
20 000 protein coding genes. Genetic variation among humans contributes to phenotypic 
variation and also to susceptibility to complex diseases. The most prevalent category of genetic 
variants is single nucleotide polymorphisms (SNPs), which are widely used as tools in genetic 
association studies.  
Various approaches can be used to study the genetic factors underlying complex traits. 
Recently, family-based approaches have been largely replaced by population based association 
studies performed most often in large case-control cohorts. By taking advantage of linkage 
disequilibrium (LD), the tendency of genetic markers to appear together more frequently than 
would be expected by chance, the majority of common genetic variation in a given locus or 
across the whole genome can be captured by selecting an appropriate set of SNPs for 
genotyping. The candidate gene approach is based on the knowledge of disease or trait biology, 
whereas genome-wide association studies performed in large study populations are hypothesis-
free approaches that target common genetic variation across the genome. In the future, also 
other types of genetic variation, such as rare variants, copy number variants (CNVs) and 
epigenetic modifications will be of increasing interest.  
In this work, variants in obesity and T2DM candidate genes were genotyped in the 
participants of the Finnish Diabetes Prevention Study (DPS). The candidate genes were selected 
based on previous research evidence demonstrating their potential role in molecular pathways 
underlying these traits. In addition to studying the effects of these gene variants on the 
phenotypes of interest, the aim of these studies was to examine the potential interactive effects 
between genetic and lifestyle factors.  
22  Review of literature 
2.1 THE HUMAN GENOME 
The first draft of human genome sequence was completed in 2001 by the international 
collaboration, the Human Genome project (1), and a more complete version of the genomic 
sequence followed 2004 (2). The haploid human genome comprises approximately 3 billion base 
pairs (bp) and contains approximately 20 000 protein coding genes (1.5% of the genome), which 
is much lower number than previously expected (2, 3). Although the functions of the remaining 
parts of the genome are currently poorly understood (4), the diversity of human genome output 
is expanded greatly by multiple levels of gene expression regulation. A wide variety of 
regulatory sequences exist locating either within the genes they regulate or in other parts of the 
genome even great distances away (5). In addition, protein-DNA and RNA-DNA interactions, 
and epigenetic modifications of DNA control gene expression (6). Furthermore, the expression 
of  the  genome is  also  regulated by small  RNA products  (miRNA and siRNA),  via  alternative  
splicing, and at translational and post-translational levels (6).  
2.1.1  Genetic variation 
As a species, humans are genetically very homogeneous, and the genomes of different 
individuals differ only by 1-3% (3). In general, the genetic differences between individuals are 
referred to as variants, and a term polymorphism is used when the minor allele has a frequency 
greater than 1%. The two or more different forms of a variation are called alleles, and haplotype 
refers to a collection of alleles arranged linearly on a single chromosome that are inherited 
together (6). The inter-individual genetic variation, acting together with environmental 
influences, accounts for variability in physiological traits and susceptibility to various diseases.  
A single genetic variant may be neutral without any detectable effect on phenotype (the 
observable characteristics of an individual), or it may result in altered expression, structure or 
function  of  the  gene  product.  Evolution  is  a  process  in  which  the  genetic  make-up  of  
populations  is  modified  over  time  and  over  generations  by  natural  selection.  This  gradual  
process  favors  individuals,  and  thus  the  genetic  variants  they  carry,  who  are  best  adapted  to  
their environments in terms of survival and reproduction.  
Human genomic variation ranges from single base pair substitutions or point mutations to 
large, microscopically visible chromosomal rearrangements. The public Single Nucleotide 
Polymorphism Database (dbSNP build 132) contains more than 30 million human genetic 
variants, mostly SNPs and small insertions/deletions (indels), but also microsatellites (7) 
Single nucleotide polymorphisms 
SNPs are the most common type of genetic variation and occur throughout the genome 
approximately at every 500-1000 bases (8). SNPs are usually bi-allelic single nucleotide variants 
in  the  DNA  sequence  that  differ  between  individuals  or  pairs  of  chromosomes  of  a  single  
individual (9). SNPs may lie within protein coding sequences, non-coding regulatory sequences, 
or intergenic regions. Synonymous (or silent) SNP locates within the coding sequence, but does 
not alter the amino-acid sequence of the protein product. Non-synonymous SNPs cause 
alterations in the amino acid sequence and may be further categorised as missense SNPs 
(resulting in change of amino acid) or nonsense (resulting in premature stop-codon and 
truncated protein product). SNPs in non-coding regions may affect phenotype through 
alterations in regulation of gene expression or splicing. SNPs are easily assayed and widely 
used as markers by genetic and genomic approaches aiming to clarify the genetic background 
of complex diseases.  
3Other types of genetic variants 
Small or large fragments of DNA may be removed (deletion), inserted (insertion), translocated 
to another location (translocation) or inversed (inversions). They range in size from one to 
thousands of base pairs and may be neutral or may affect phenotype with varying degrees. 
CNVs are large duplications, insertions, deletions and translocations of 1 kb to several million 
bp, while variants involving 100-1000 bp are referred to as indels (10). CNVs are turning out to 
be much more frequent than expected and are already implicated in certain complex diseases, 
such as Chrohn’s disease, autism and schizophrenia (10, 11). Genomic variants are even larger-
scale structural variants that have been implicated in syndromic anomalies and diseases, and 
are usually caused by de-novo chromosomal rearrangements unlike CNVs, which are most 
commonly  inherited  (10).  Their  role  in  population  diversity  and  disease  states  is  currently  
under extensive investigation. Micro- and minisatellites are highly polymorphic tandem repeats 
that vary among individuals and are utilised in genetic mapping studies (12). 
Resources of human genetic variation 
The International HapMap project was launched in 2002 with a goal to catalogue patterns of 
common genetic variation and LD in different human populations (13). LD describes a situation 
where alleles occur together more often than expected by chance alone, and may be exploited in 
planning genetic  association studies.  In  phases  I  and II  of  HapMap,  over  3.1  million common 
SNPs were genotyped in 270 individuals from four geographically distinct populations (14). In 
phase III, this public resource was expanded to include SNPs with lower allele frequency as 
well as CNVs, and common SNPs from seven additional populations (15). 
The 1000 Genomes Project aims at identifying and genotyping all  forms of human genomic 
variation by combining low-coverage whole-genome sequencing, array-based genotyping, and 
targeted high-coverage sequencing of all coding regions in 2500 individuals from five major 
human population groups (16). The pilot phase of the project described allele frequencies, 
locations and local haplotype structures for 15 million SNPs, 1 million short indels and 20 000 
structural variants. Based on the results of the pilot study, each human genome is heterozygous 
for 50-100 variants implicated in inherited diseases according to the Human Gene Mutation 
Database, and approximately 250-300 genes per individual are affected by loss-of-function 
variants (16). 
Epigenetics 
Epigenetics refers to chemical changes of the DNA molecule that do not alter the primary 
sequence of the genome, but are heritable during cell division (17). The best-known examples of 
epigenetic modifications are the methylation of cytosines in cytosine-guanine di-nucleotides 
(CpG) and the modification of DNA packing proteins, histones, both of which may affect DNA 
transcription (17). Epigenetic modifications are affected by environmental and genetic factors, 
and the understanding of their role in the pathogenesis of complex diseases, most notably 
cancer, has advanced substantially over the past years (6, 17). 
2.2 EVOLUTIONARY PERSPECTIVE TO OBESITY AND TYPE 2 DIABETES  
2.2.1 Evolutionary perspective 
During evolution, the human genome has been subjected to selective pressures relating to 
ecological  conditions,  such  as  changes  in  food  supplies  and  climate.  Part  of  our  genome  was  
modified even before the emergence of our genus, whereas parts of it have changed relatively 
recently. Understanding the genetic adaptations relating to diet and metabolism is crucial in 
order to understand current nutritional needs of humans and the underlying mechanisms of 
complex diseases associated with modern diets and lifestyle (18, 19).  
4Variety and flexibility are common characteristics of the diets of humans as well our primate 
relatives. The diets of wild chimpanzees, our closest extant relatives, are low in fat compared to 
diets of contemporary humans, and consist mainly of fruits, but also include leaves, nuts and 
insects, and occasionally minor amounts of meat (18, 20, 21). Captive chimpanzees with reduced 
levels  of  physical  activity  and diet  rich  in  animal  tissues  and dairy,  are  susceptible  to  obesity  
and have increased risk of cardiovascular disease (CVD) (20, 22) 
Our evolutionary lineage (hominin) diverged from that leading to common chimpanzees and 
bonobos approximately 6 million years ago (mya) (23). The major dietary shifts in our species’ 
history include: adaptations to new food sources of woodlands and savannah (~4.4 mya), 
introduction of meat eating (~2.5 mya), inventing cooking (~1.5 mya-800 000 years ago), 
dispersion from Africa to highly variable habitats (~60 000 years ago), agricultural revolution 
(starting ~10 000 years ago) and industrial revolution (~200 years ago) (19, 21). All of these 
events  go  hand  in  hand  with  significant  changes  in  anatomy,  culture,  social  structures  and  
technology, and are often connected with changes in global climate.  
The energy expenditure level of early hominins was high and their plant-based diets 
included  a  wide  range  of  food  resources  with  sufficiently  macro-  and  micronutrients,  low  fat  
content and high intake of fibre (21). By 2.5 mya hominins were becoming omnivorous with 
meat consumption providing higher caloric gains, but also increases in protein, iron and other 
important dietary components (20, 24). The introduction of cooking, on the other hand, 
increased the digestibility of both plant and animal derived foods (19, 25). Both meat eating and 
cooking, have been suggested to have been facilitating the increase in brain size and the 
coincidental reduction in gut size (19, 20, 24, 25). Moreover, since the brain is an energetically 
expensive organ, encephalisation was likely associated with increased body fatness to ensure 
sufficient energy stores especially during infancy, childhood, pregnancy and lactation (24, 26, 
27). Relating to this, the asymmetry in reproductive cost between men and women may have 
resulted in differential adaptive strategies regarding fat storage, and may explain the current 
differences in adipose tissue (AT) distribution and metabolism (27).  
The first anatomically modern human appeared approximately 200 000-150 000 years ago in 
eastern Africa (28). The migration out of Africa was accompanied by a significant population 
bottleneck. The size of the migrating founder population is estimated to have been 
approximately 1000 effective individuals, which together with the subsequent rapid population 
expansion, explains the low genetic diversity and high LD observed across all contemporary 
non-African populations (28). Modern humans (mostly) replaced the existing hominin species 
in Europe and Asia and colonised the entire globe by 25 000 years ago through large numbers of 
subsequent population bottlenecks of smaller amplitude (28). Since then, human populations 
have adapted to a wide variety of habitats with very different food sources, climates and 
ecology.  
The diets of the Paleolithic hunter-gatherers varied greatly with latitude and season, and 
humans remained remarkably flexible eaters (26, 29). Generally, the amount of dietary 
carbohydrates varied inversely with meat intake, diets were high in protein, polyunsaturated 
fat, fiber, and most micronutrients, but low in saturated fat and sodium (18, 29). In addition, the 
energy expenditure was high compared to modern day settings. According to some estimates 
hunter-gatherer males typically spent 19.6-24.7 kcal/kg/day in physical activity whereas the 
corresponding value for the modern sedentary office worker is 4.4 kcal/kg/day (30).  
2.2.2 Agricultural revolution and modernisation 
Approximately 10 000 years ago agriculture, based on plant and animal domestication, began in 
various parts of the world and resulted in major changes in lifestyle and dietary patterns (26). In 
terms of nutrition, the breadth of food sources decreased dramatically with increased reliance 
on a few species of high-carbohydrate cereal crops and tubers (19, 21, 26). In addition, the 
supply of food fluctuated throughout the year and severe periodic famines were common. 
Analyses of skeletal materials suggest significantly reduced adult stature and a number of 
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agriculturalists (21, 26).  
While early agriculture was labour intensive, industrial revolution and mechanisation has 
resulted in dramatic decrease in the energy cost of daily activities. Although dietary breadth has 
been at least partly restored and fluctuations in food availability reduced, modern diets have 
created another set of deleterious metabolic problems, including obesity and T2DM epidemics 
(21). The availability, a proxy for actual consumption, of fats, oils, meat, cheese, and frozen 
dairy products has increased in the USA over the past century (31). Increasing 10-year trends in 
total energy supply per capita has been found in most high-income countries and China from 
the mid-1980s to the mid-1990s (32). More specifically, consumption of highly processed and 
energy-dense foods and drinks has increased rapidly in higher-income countries during the 
past decades (33). In addition, general trends of occupational and transportation physical 
activity are decreasing and the proportion of sedentary individuals is increasing in many 
industrialised countries (34, 35).  
2.2.3 The mismatch between genes and lifestyle
Changes in our lifestyle,  induced by the agricultural revolution and especially those that have 
followed modernisation, have been extremely rapid. The pace of genetic adaptation generally 
occurs far more slowly even though a few relatively recent genetic adaptations have been 
described. The resulting mismatch between our genome and the modern environment is 
hypothesised to explain the increased prevalence of chronic degenerative diseases observed 
today. Few of the most important hypotheses concerning this mismatch are discussed here 
briefly.  
The thrifty genotype hypothesis 
According to the thrifty genotype hypothesis, proposed by Neel in 1962, the ability to store 
energy efficiently during feast periods gave a selective advantage to our hunter-gatherer 
ancestors  during  subsequent  famine  periods.  Neel  suggested  that  gene  variants  conferring  
efficient energy storage were favoured by natural selection, but are deleterious in modern 
environment where high caloric foods are continuously available predisposing their carriers to 
obesity and T2DM (36). Neel emphasised the role of quick insulin trigger after a meal in 
enhancing the glucose preservation. In contrast, according to the “not-so-trifty genotype” –
hypothesis, muscle insulin resistance was considered evolutionarily beneficial in maintaining 
muscle mass during famine (37). In both models, temporary hyperinsulinemia and insulin 
resistance are considered to be survival mechanisms during fluctuations of energy availability, 
that only become pathogenic and persistent under conditions of surplus supply of energy (38).  
Several aspects of Neel’s original hypothesis have been challenged afterwards. It has been 
pointed out that famines were probably rare in pre-Neolithic populations as the hunter-
gatherers exploited a wide variety of food sources and were able to change location in order to 
follow food resources (39, 40). Moreover, it has been suggested that famines were too rare and 
insufficient to act as a selective force on survival, and that random genetic drift, in combination 
with  lack  of  selection,  explains  the  genetic  predisposition  to  obesity  (41)  or  that  the  target  of  
natural selection was not survival, but reproduction during regular famines of post-agricultural 
era (39). Others have emphasised the role of the large human brain in favouring enhanced 
energy storage. The energy requirements of the brain are largest in infancy, when brain 
metabolism accounts for >60% of resting metabolic rate, and early childhood. Early childhood 
also affect indirectly maternal energy metabolism through lactation (40, 42, 43).  
The thrifty phenotype hypothesis 
The “thrifty phenotype” hypothesis (or the developmental origins hypothesis), on the other 
hand, states that conditions during specific windows of early development can have 
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susceptibility later in life (44). The developmental origins hypothesis is supported by numerous 
epidemiological studies demonstrating a link between early development and the occurrence of 
diseases later in life (45). The mechanism linking prenatal conditions to later disease risk may 
involve epigenetic modifications (17).  
Our genetic legacy 
Metabolic thriftiness, genotypic or phenotypic, may be considered as an ability to reduce energy 
expenditure or to store energy rather than spend it (46). Bouchard has suggested five non-
mutually exclusive categories for potential thrifty genes: 1) genes involved in regulation of 
metabolic rate or thermogenesis, 2) genes involved in appetite and satiety regulation, 3) genes 
predisposing to physical activity vs. inactivity, 4) genes regulating lipid oxidation and 5) genes 
involved in adipogenesis and lipid storage capacity (47).  
As a species, humans represent general thriftiness compared with many other species, 
reflecting the metabolic adaptations early in our evolutionary history (46). We have lower 
muscle mass and higher adiposity compared with other primates and other mammals (43). This 
may be regarded as a thrifty trait, since the energy requirement of AT is significantly lower 
compared with that of muscle tissue (42). In addition, fat provides energy storage that buffers 
against environmental fluctuations in nutritional resources (42, 43). Human infants have higher 
adiposity compared with any other mammalian species and adiposity continues to increase 
during the first months declining thereafter in early childhood (43), and increasing again during 
adolescence when sexual dimorphism in adiposity emerges (46).  
Population differences in susceptibility to obesity may be attributable to genetic adaptations 
to specific ecologic niches that have emerged since the last common ancestor (46). These 
differences reflect more localised selective pressures and affect different components of human 
metabolism (40). Negative selection acts to decrease population differences globally at amino 
acid altering mutations, whereas positive selection increases population differences through 
regional adaptations primarily at nonsynonymous and regulatory variants (48). For this reason, 
it is important to remember that alleles associated with complex diseases could also be 
geographically restricted highlighting the importance of analysing multiple populations with 
different demographic histories. In the case of complex diseases, the risk alleles are not 
necessarily new mutations, but rather ancestral alleles whose effects have become 
disadvantageous along with recent lifestyle changes (48).  
2.3 COMPLEX DISEASES AND QUANTITATIVE TRAITS 
Complex human diseases and quantitative traits are caused by multiple genetic, environmental 
and lifestyle related factors as well as their multifaceted interactions. They aggregate in families, 
indicating a genetic component, but do not follow clear Mendelian inheritance patterns, and are 
to a large extent influenced by non-genetic factors. Unlike in single gene disorders, the presence 
of a particular gene variant is neither necessary nor sufficient to cause a disease, but instead 
confers a modest alteration in disease susceptibility. The vast majority of all human diseases 
and quantitative phenotypic traits, including certain types of common cancers, T2DM, CVD, 
asthma, autoimmune diseases, obesity and height, have a complex aetiology. The contribution 
of genetic factors and the genetic architecture varies across complex phenotypes. The discussion 
here is mostly limited to obesity, T2DM and related traits.  
Heritability  
Heritability is an important parameter that estimates the proportion of the total phenotypic 
variation of a complex trait that can be attributed to genetic variation (49). Heritability can be 
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of genetic and non-genetic factors. Heritability does not, however, describe the magnitude of 
each component and is always specific to a particular population and environment (50). 
Genetic background of complex phenotypes 
During  the  past  few  years  genome-wide  studies  have  been  successful  at  identifying  SNPs  
associated with common complex diseases and quantitative traits. The genetic variants 
characterised thus far are mostly common (minor allele frequency, MAF>5%) and thereby fit the 
traditional “common disease–common variant” –hypothesis, which assumes that common 
diseases are largely attributable to allelic variants present in 1-5% of the population (51). 
Individually such variants have only small effects on the disease risk, but collectively they may 
increase the risk substantially. Rather than affecting the structure or function of the gene 
product itself, these variants often have modest direct or indirect effects on gene expression (10-
20%) or splicing (49, 52). On the other hand, the common variants currently identified explain 
only a small proportion, less than 10%, of genetic variance for most complex traits (53). This 
leads to the conclusion that either the heritability measures of complex traits are overestimated 
or different types of gene variants explain significant portion of the genetic component, and 
consequently, the focus is now gradually shifting from common SNPs to other types of genetic 
variants. Importantly, however, each complex disease and phenotype has its own unique 
genetic architecture, and thus diverse strategies may be necessary in finding the missing 
heritability in each case. 
It has been hypothesised that a significant part of the unidentified genetic component of 
complex  traits  is  accounted  for  by  rare  and  diverse  loss-of-function  alleles,  which  in  a  
homozygous state would have severe consequences (explaining the low population 
frequencies), but in heterozygous state would lead to a 50% loss in expression levels (49). The 
effects of these variants are too small to display clear inheritance patterns in family-based 
studies, but on the other hand, these variants are too rare to be captured by traditional 
association strategies (49). Efforts to systematically identify these variants are now emerging 
and the early results have already revealed that the low-frequency (MAF 0.5-5%) and rare 
(MAF<0.5%) variants by far outnumber the common variants in the genome, and are likely to 
contribute significantly to genetic component of many complex diseases (16). In addition to 
common and rare variants, epigenetic modifications, CNVs and gene-gene interactions may 
contribute significantly to the phenotypic variation and disease susceptibility in the population 
(4).  
Characterising the genetic basis of each complex condition is further complicated by genetic 
heterogeneity and pleiotropy. Similar phenotypes may result from distinct combinations of 
individually rare variants. Moreover, separate variants within a given gene (allelic 
heterogeneity)  or  in  different  genes  of  same  or  related  molecular  pathways  (locus  
heterogeneity) may lead to the same disorder. Finally, the same genetic variant may have 
pleiotropic  effects  on  multiple  phenotypic  traits  and  may  thus  lead  to  different  clinical  
manifestations in different individuals. It is thus likely that many complex human diseases 
represent a collection of aetiologically distinct conditions with different underlying genetic 
components. Identifying genetic variants underlying complex diseases will help in separating 
molecular subtypes from each other, which in turn has important implications for disease 
prevention and treatment. 
2.4 METHODS TO STUDY GENETICS OF COMPLEX DISEASES 
The rapid technological developments, declining costs and availability of larger sample sizes 
have induced major transformations in the field of disease gene discovery. Moreover, 
availability of public resources, such as the dbSNP (7), the HapMap project (15), and the 1000 
8genomes project (16) has proven invaluable for designing genetic association studies. Over the 
past decades, research has gradually progressed from family-based linkage studies via 
candidate gene approaches to genome-wide association studies (GWAS). In the future, the 
greatest  challenges  will  involve  setting  global  criteria  for  phenotype  data  and  also  managing  
and analysing enormous amounts of sequence data (3). 
2.4.1 Family-based linkage studies 
Genetic linkage refers to coinheritance of a genetic marker with a phenotypic trait in a family 
with multiple affected members (54). The basic idea is to enrich individuals with common 
genetic background and thus to increase statistical power to detect a genetic effect. Genetic 
markers  are  followed  in  a  pedigree  with  the  aim  of  finding  markers  that  lie  close  to  the  
unknown disease-causing variation. Linkage studies are powerful at locating even relatively 
rare variants with large effect sizes, but have limited power to detect variants with modest 
effect sizes. Other shortcomings of family studies include difficulty of collecting large number 
of families with sufficient numbers of affected individuals, and complexity of computational 
methods. Moreover, the chromosomal regions identified are large, often comprising even 
hundreds of genes, and identifying the disease associated genes and variants is challenging (55). 
In case of obesity and diabetes, family-based studies have been succesful in identifying variants 
responsible for extreme and early-onset forms that segregate in families, such as maturity onset 
diabetes of the young (MODY), mitochondrial diabetes with deafness, neonatal diabetes, and 
rare forms of severe childhood obesity (56). 
2.4.2 Population based association studies 
Genetic association is defined by a non-random occurrence of a genetic marker with a trait (54), 
and an association between genetic variant and phenotype is expected, when the variant has a 
functional effect or when it is in LD with a functional variant (57).  
Compared with family-based studies, recruiting large numbers of unrelated subjects is often 
easier and genetic association studies usually result in more accurate localisation of the 
functional variant (58). On the other hand, population stratification, locus or allelic 
heterogeneity, and false-positive findings due to the large number of tests performed may lead 
to erroneous conclusions (58).  
Modern large-scale population based studies have proven powerful at identifying gene 
variants  with  small  to  modest  effect  sizes,  but  until  recently,  the  number  of  disease  
susceptibility loci that could be replicated in independent study populations was limited. The 
reasons for irreproducibility of results can be explained by several contributing factors: lack of 
statistical power, inappropriate selection of candidate loci, failure to capture variation across the 
whole gene region, low threshold for significance and over-interpretation of results (59).  
Linkage disequilibrium and haplotype analysis 
A key aspect in performing association studies is indirect association, which makes use of the 
LD patterns across the genome (60). If two loci are inherited together more often than would be 
expected by change, they are said to be in LD. The further apart the SNPs are located, the more 
likely they are to be separated by recombination, and consequently strong LD indicates that 
SNPs are likely to be inherited together. In addition to physical distance between the loci, LD is 
affected by cross-over rate and the number of generations since the mutation occurred or was 
introduced  with  younger  populations  demonstrating  stronger  LD  on  average  (60).  Two  
commonly used measures of LD are D’ and r2. D’ is a unidirectional measure of LD (i.e., it is 
possible to predict the genotype of SNP2 from SNP1, but not the other way around), whereas r2
is bidirectional measure of LD (i.e. it is the traditional correlation of SNP1 and SNP2) (60). 
A subset of SNPs (tagSNPs) in a genomic region of interest or across the whole genome are 
selected for genotyping, and taking advantage of the known LD patterns, the untyped common 
SNPs are imputed from tagSNP genotypes (9, 61). Therefore, in genetic or genomic association 
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but  merely  mark  the  genomic  region  harbouring  the  true  functional  variant.  The  power  to  
detect the causal SNP by a tagSNP depends on the LD between the SNPs, allele frequencies and 
the association model.  
The HapMap project has increased the understanding of LD patterns across the genome in 
different human populations and illustrates that by selecting maximally informative, non-
redudant tagSNPs, genotyping of <500 000 SNPs may allow a nearly complete survey of all 
common genetic variability (62). 
Association between genetic variants and a trait of interest may be analysed singly or by 
using haplotypes consisting of multiple variants. When study populations consist of unrelated 
individuals, haplotypes cannot be deduced directly but need to be inferred by statistical tools 
such as THESIAS (63). Analysis method based on haplotypes may be more efficient than 
separate analyses of individual markers in presence of multiple susceptibility alleles, 
particularly when LD between the variants is weak (64). In addition, in some situations 
haplotypes consisting of tagSNPs may more efficiently capture untyped common genetic 
variants in the region (65). On the other hand, even if haplotype analysis may be more 
informative than single SNPs, the power of haplotype analysis may be reduced by large 
number of haplotypes that needs to be studied.  
Different study designs used in association studies 
Most association studies are based on a case-control design, in which genotype frequencies of 
the variants are compared between cases, expressing the trait of interest, and controls, without 
the trait, to determine if any alleles are over-represented in either group. Compared with other 
types of study designs, case-control studies are often more affordable and easier to conduct, but 
may be prone to a number of biases mostly relating to the lack of comparability between cases 
and controls (55). More specifically, cases are typically sampled from clinical sources and may 
not be representative group as fatal, mild or silent cases are not included. On the other hand, 
the controls should be drawn from the same population and represent individuals who are 
truly free of the disease trait, but who are nevertheless at risk of developing the disease or trait.  
In prospective studies, extensive baseline information on participants is gathered, these 
individuals are followed, and the incidence of a disease is assessed with the advantage that all 
participants are ascertained and followed up in the same way (55). While large case-control 
studies are suitable for the initial identification of susceptibility SNPs, prospective studies may 
be more useful in qualifying the true risk of known variables (66).  
Candidate gene studies 
The earliest forms of population-based association studies were candidate gene studies that 
focused on variants within a biologically plausible candidate gene(s). This approach limits the 
number of tests that needs to be performed, but is restricted to genes involved in known 
molecular pathways. Moreover, it excludes genomic regions outside gene loci, which may 
nevertheless have important regulatory functions (9). 
In the earliest candidate gene studies only one or few variants, often known to be functional, 
were genotyped, whereas in later studies the tagSNP approach was used for variant selection in 
order to cover all common variation in the locus of interest. This approach helps to minimise 
the  number  of  SNPs  that  need  to  be  genotyped,  but  lowers  the  power  compared  to  testing  
functional SNPs directly (57) 
Numerous T2DM and obesity variants have been identified using this approach, but only a 
small fraction has been validated in replication studies. Examples of T2DM associated genes 
successfully identified through candidate gene studies include PPAR and KCNJ11, which have 
been subsequently confirmed by GWAS (67-69). 
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Genome-wide association studies  
In GWAS, a large number of variants across the whole genome are genotyped in a large group 
of individuals. By utilising the information on haplotype maps of human populations and 
careful  selection  of  tagSNPs,  GWAS  can  be  designed  to  cover  a  large  part  of  the  common  
genetic variants in the whole genome (49, 54). GWASs are generally multistaged studies, where 
the top SNPs from discovery cohort are subsequently genotyped in a replication cohort (9). The 
SNPs that are successfully replicated are then meta-analysed in the combined discovery and 
replication cohort, and those that reach the level of genome-wide significance (p<0.05 x 10-8) will 
be studied further by other methods (9).  
In general, the SNPs identified by GWASs are common (MAF>5%), have modest effect sizes, 
and are not highly differentiated across populations (52). However, GWASs do not easily 
identify  rare  risk  alleles  that  exist  in  a  given population (49).  Another  weakness  of  GWASs is  
that testing a large number of polymorphisms is required, which decreases the power to 
identify associations, meaning that a large number of cases are required to identify associated 
variants. Moreover, so far GWASs have been largely limited to populations of European 
descent (9).  
Owing to GWASs, the number of validated associations between genetic variants and 
complex traits and diseases has increased dramatically during the past few years, and the list of 
associations is continuously updated in the National Human Genome Research Institute’s 
catalogue of published GWASs (70). The majority of the currently known genes associating with 
T2DM have been identified through GWASs (54), which have implicated new pathways in the 
development of T2DM. An example is provided by a missense variant in SLC30A8 gene which 
encodes a zinc transporter crucial for insulin packaging and secretion in beta cells (9, 71). 
Similarly, GWAS approach revealed the association between T2DM and variants in the TCF7L2
gene (72), which was at the time not considered a candidate gene for T2DM, but has thereafter 
been shown to modulate beta cell function (73).  
Molecular evolutionary methods 
Evolutionary  approaches,  not  requiring  prior  assumptions  of  the  specific  genes  targeted  by  
natural selection, may be used to identify genetic loci associated with complex diseases (74). 
Natural selection generates detectable patterns against the genome-wide background of 
neutrally evolving loci and investigating haplotype structures and allelic architecture can reveal 
signals of positive selection, such as reduced haplotype diversity (19, 74). Identifying the genetic 
adaptations  relating  to  nutrition  and  metabolism  may  help  in  identification  of  risk  alleles  for  
modern diseases, such as obesity and T2DM (74).  
Future directions  
Since GWASs only capture the common variation of the genome, different approaches need to 
be developed in order to understand the role of other types of genetic variants in human 
phenotypic variation. The next generation technologies have reduced the costs and time 
requirements of sequencing, and systematic efforts to catalogue rare and structural sequence 
variants by exome and whole genome sequencing are already ongoing (15, 16). Moreover, 
epigenetic modifications controlling the potential of the genome to be transcribed may have a 
significant impact on complex human diseases (17). In the future, integrating epigenomic and 
genomic data may reveal genomic risk factors that are more powerful than those based on 
sequence variants alone (17). Finally approaches, such as transcriptomics, proteomics and 
metabolomics aim at integrating data from multiple levels of biological processes in order to 
clarify the interactions among gene variants and between genetic and environmental factors. 
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2.5 OBESITY 
2.5.1 Definition and prevalence 
Overweight and obesity are characterised as an excess accumulation of body fat. Body mass 
index (BMI) is the most commonly used index to classify overweight and obesity at population 
level, and is calculated as a weight in kilograms divided by squared height in meters (kg/m2). 
Obesity is generally defined as BMI  30 and overweight as BMI25 (75). Other simple 
anthropometric measurements, such as waist circumference (WC) and waist-to-hip ratio 
(WHR), may be used to define obesity and also give a more precise picture of body fat 
distribution. For more accurate measurement of body composition more laborious and costly 
methods, such as bioelectrical impedance, dual energy X-ray absorptiometry, quantitative 
computed tomography, underwater weighing, magnetic resonance imaging or computed 
tomography, can be used (76).  
The prevalence of obesity is increasing rapidly worldwide (77). According to WHO 
approximately 1.5 billion adults (aged over 20 years) were overweight. Of those more than 200 
million men and nearly 300 million women were obese in 2008 (75). Moreover, almost 43 
million children under the age of 5 years were overweight in 2010 (75). WHO further predicts 
that by 2015, approximately 2.3 billion adults will be overweight and more than 700 million will 
be obese (75). In Finland, the prevalence of obesity increased from 11.3% to 20.7% in men and 
from 17.9% to 24.1% in women aged  30 years between the two national surveys performed in 
1978-1980 and 2000-2001 (78). However, more recent observations indicate that the prevalence 
of obesity may be, in fact, decreasing among 45-74 year old Finns (79).  
Obesity is associated with an array of adverse metabolic conditions, such as insulin 
resistance, T2DM, hypertension, dyslipidaemia, atherosclerotic vascular disease, fatty liver 
disease and certain types of cancers (80). Successful long-term weight loss decreases the risk of 
obesity related co-morbidities (81), but has proven difficult to achieve and maintain (82).  
2.5.2 Environment vs. genes in the development of obesity 
The modifiable risk factors of obesity and weight gain are well recognised. Increased energy 
intake and decreased energy expenditure generally lead to storage of excess energy as fat, and 
the lifestyle changes that have occurred during the past decades largely explain the rapid 
increase in prevalence. Nevertheless, a strong genetic predisposition exists as suggested by the 
fact that some individuals seem to be more susceptible to weight gain than others in the current 
obesogenic environment (83). There are also racial differences in the prevalence of obesity that 
cannot be explained by environmental and lifestyle factors alone (84). Furthermore, the data 
from experimental twin studies support the notion that predisposition to obesity has a strong 
genetic component (85, 86). The heritability estimates for BMI range from 40 to 70% (87) and are 
comparable for other measures of adiposity (88, 89). 
2.5.3 Genetics of obesity 
The sporadic cases of monogenic obesity are caused by rare functional mutations in genes 
encoding appetite regulating proteins, such as leptin (LEP), leptin receptor (LEPR), 
melanocortin 4 receptor (MC4R), and pro-opiomelanocortin (POMC), highlighting the key role 
of neuronal regulation of overall adiposity (83, 90). These mutations often lead to a 
dysfunctional gene product, and severe early-onset phenotype (90). Although, common 
variants in several of these genes are also associated with common obesity (83, 91), its polygenic 
background is still fairly poorly understood.  
An ever increasing number of common SNPs that associate with common obesity and related 
phenotypes have been identified through GWASs (70). A list of confirmed obesity associated 
loci identified through GWASs is presented in Table 1. Recently, a two-staged GWAS meta-
analysis of up to 249, 796 individuals of European descent performed by the GIANT consortium 
(Genetic Investigation of ANthropometric Traits) confirmed 14 known loci and identified 18 
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novel loci associating with BMI (92). It has been estimated that altogether the common variants, 
including those already identified as well as those yet unidentified, only account for 6-10% of 
heritability of BMI (92). Although many of the genes identified by GWAS are implicated in 
neuronal functions (56), a substantial part of the variants are not located near genes involved in 
known obesity-related molecular pathways, suggesting that much of the biology of obesity 
remains unknown (92).  
Whereas overall adiposity seems to be associated with variants implicated in hypothalamic 
functions,  many  of  the  variants  associating  with  fat  distribution  lie  close  or  within  genes  
implicated in adipocyte development and function (56). In other words, fat distribution seems 
to be controlled by at least partly distinct genetic factors. Interestingly, many of the variants 
show markedly stronger effects in women compared with men (56, 93). 
The fat mass and obesity-associated gene (FTO) is regarded the best established genetic risk 
factor for common obesity. It was identified in 2007 through GWAS (94) and the association 
with obesity has been replicated thoroughly in independent study populations (95). 
Interestingly, variation in the MC4R gene, associated with monogenic obesity, also seem to 
contribute less severe and more complex forms of obesity (91). 
Table 1. Loci associating with obesity, BMI and body composition that have been identified through 
GWAS.
Nearest 
gene(s) 
Full name Trait Putative functions of the gene 
product 
Reference
BDNF Brain-derived neurotrophic factor BMI Neuronal function, possible role in 
regulation of stress response and 
in the biology of mood disorders 
and eating behaviour 
(92, 96)
FAIM2/
BCDIN3D
Fas apoptotic inhibitory molecule 
2/ BCDIN3 domain containing 
BMI, WC Unknown (92, 96, 97)
FTO Fat mass and obesity associated extreme
and early- 
onset 
obesity, 
BMI,
obesity-
related 
traits
The exact function unknown, may
be involved in nucleic acid 
demethylation, mRNA regulated 
by feeding and fasting in mice 
(91, 92, 94,
96-105)
GNPDA2 Glucosamine-6-phosphate 
deaminase 2 
BMI Catalyses the reversible 
conversion of D-glucosamine-6-
phosphate into D-fructose-6-
phosphate and ammonium, 
expressed at high levels in brain 
and hypothalamus 
(92, 103)
KCTD15/
CHST8 
Potassium channel tetramerisation 
domain containing 15/ 
carbohydrate (N-
acetylgalactosamine 4-0) 
sulfotransferase 8 
BMI KCTD15: Unknown, CHST8: 
sulfation of carbohydrates 
(92, 96, 103)
LYPLAL1 lysophospholipase-like protein 1 WHR,
adiposity 
possibly acts as a TG lipase,
reported to be up-regulated in 
subcutaneous AT of 
obese subjects 
(93, 106)
MC4R Melanocortin 4 receptor BMI,
extreme 
obesity, 
obesity, 
WC
Interacts with adrenocorticotropic 
and MSH hormones and is 
mediated by G proteins, 
associated monogenic obesity 
(91, 92, 96,
97, 99, 102, 
103, 107) 
Table 1. continues 
13
Table 1. continued 
MTCH2/
NDUFS3/
CUGBP1
mitochondrial carrier 2/ NADH 
dehydrogenase (ubiquinone) Fe-S 
protein 3, 30kDa (NADH-
coenzyme Q reductase)/ CUGBP, 
Elav-like family member 1 
BMI MTCH2: may function in cellular 
apoptosis, NDUFS3: mitochondrial 
function, CUGBP1: regulation of 
alternative splicing and may be 
involved in mRNA editing, and 
translation 
(92, 103)
NEGR1 Neuronal growth regulator 1 BMI expressed at high levels in brain 
and hypothalamus, involved in 
neuronal outgrowth, candidate 
CNV identified 
(92, 96,
103)
NRXN3 neurexin 3 BMI, WC nervous system cell adhesion 
molecule 
(92, 97,
100)
SEC16B/
RASAL2
SEC16 homolog B (S. cerevisiae)/ 
RAS protein activator like 2 
BMI Involved in organisation of 
transitional ER sites and protein 
export, RASAL2: functions as 
activator of Ras superfamily of 
small GTPases 
(92, 96)
SH2B1/ 
APOB48R/
SULT1A2/ 
ATXN2L/
TUFM/
ATP2A1
SH2B adaptor protein 1/ 
apolipoprotein B receptor/ 
sulfotransferase/ family, cytosolic, 
1A, phenol-preferring, member 2/ 
ataxin 2-like/ Tu translation 
elongation factor, mitochondrial/ 
ATPase, Ca++ transporting, 
cardiac muscle, fast twitch 1 
BMI SH2B1: implicated in leptin 
signaling, APOB48R: macrophage 
receptor that binds to the 
apolipoprotein B48 of dietary 
lipoproteins rich in TG, 
SULT1A2:encodes phenol 
sulfotransferase with thermostable 
enzyme activity, ATXN2L: ataxin 
type 2 related protein of unknown 
function, TUFM: participates in 
protein translation in 
mitochondria, ATP2A1: involved in 
muscular excitation and 
contraction 
(92, 96,
103)
TFAP2B Transcription factor AP-2 beta BMI, WC Transcription factor preferentially 
expressed in AT, over-expression 
leads to IS via enhanced glucose 
transport and increased lipid 
accumulation and down-regulates 
expression of adiponectin  
(92, 93)
TMEM18 transmembrane protein 18 BMI Possibly involved in cell
movement, expressed in 
hypothalamus 
(92, 96,
103)
AT, adipose tissue; BMI, Body mass index; CNV, copy number variant; ER, endoplasmic reticulum; MSH, melanocyte-
stimulating hormone; WC, waist circumference, WHR, waist-to-hip ratio; IS insulin sensitivity 
Adipose tissue 
White AT functions as an energy storage buffering against fluctuations in energy supply in the 
long term (40). Energy is stored as TG during nutritional abundance and released as free fatty 
acids (FFAs) during nutritional scarcity. In order to store energy, appetite must increase beyond 
that required by energy expenditure, and indeed humans, as well as many other species, are 
able to gain weight rapidly when food is available, suggesting an evolutionary mechanism for 
seasonal storage of calories (40). Importantly, nowadays AT is also recognised to be an 
important endocrine organ having a central role in regulating various metabolic processes 
through secretion of bioactive regulatory molecules, adipokines (108).  
Two types of white AT with distinct metabolic characteristics and adipokine secretion 
profiles can be distinguished in humans, namely intra-abdominal and subcutaneous AT (109). 
Intra-abdominal AT, which is also called visceral AT, is located in peritoneal cavity and is more 
active metabolically. It exists in all mammals and comprises 20% of fat in normal weight men 
but only 6% in women (110). High intra-abdominal fat is associated with central fat distribution 
and is an independent risk factor for metabolic syndrome and T2DM (110, 111). Subcutaneous 
AT is located beneath the skin. In addition smaller local adipocyte depots are associated with 
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various  organs,  such  as  the  heart  and  kidneys  (109).  Subcutaneous  AT  located  in  lower  body  
regions is unique to humans, especially women. It is less metabolically active and evolutionarily 
linked to the high costs of human reproduction (40, 112).  
In addition to adipocytes, AT is composed of distinct cell types, such as adipocyte precursors, 
lymphocytes, macrophages, fibroblasts and stromal vascular cells (109). The cellular 
composition as well as the phenotypes of individual cells in AT may alter as a result of obesity 
(109). Most notably, the AT of obese is characterised by both adipocyte hypertrophy (increased 
cell size) and hyperplasia (increased cell number) (108). The number of adipocytes is set during 
childhood and adolescence which is why hypertrophy is thought to be the most important 
mechanism  of  increase  in  fat  depots  in  adulthood  (113).  Adipocyte  hypertrophy  results  in  
altered intracellular signalling and dysregulated adipokine production (108). Moreover, obesity 
is associated with increased macrophage infiltration to AT, and phenotypic switch of AT 
macrophages to more pro-inflammatory state (108, 114). Endothelial cell activation in inflamed 
AT results  in  production of  cell  adhesion molecules,  chemokines  and cytokines  which further  
exacerbate inflammation (108). Increased evidence therefore indicates that obesity causes 
chronic low-grade inflammation, which contributes to systemic metabolic dysfunction and 
development of obesity linked disorders (109). Moreover, in obese individuals, increased 
release of FFAs leads to impaired beta cell function and induces insulin resistance by inhibiting 
insulin-stimulated glucose uptake in skeletal muscle, and by stimulating gluconeogenesis in 
liver (115).  
Adipokines 
The regulatory molecules produced and secreted by different cellular components of AT are 
collectively called adipokines. The most important members of this functionally diverse group 
of molecules are presented in Table 2. Adipokines play important roles in modulation of 
processes such as inflammation and energy metabolism, and a balanced production of different 
adipokines is crucial for maintaining systemic metabolic homeostasis (109). In obesity, the 
production of adipokines becomes dysregulated leading to locally and systemically altered 
immune responses, which are causally associated with obesity-related comorbidities (109).  
2.6 TYPE 2 DIABETES (T2DM) 
2.6.1 Definition and prevalence 
Diabetes is a state of chronic elevation of blood glucose levels and is classified into several 
distinct categories. The underlying causes of hyperglycaemia are defects in insulin secretion, 
tissue responses to insulin, or both (117).  
Type 1 diabetes is an autoimmune disease, in which insulin producing beta cells are 
destructed (117). T2DM is much more prevalent category, accounting for 90-95% of diabetic 
individuals,  and is  caused by combination of  insulin  resistance  and inadequate  compensatory 
insulin secretion by beta cells (117). In addition, several diabetes types with monogenic defects, 
usually in beta cell function, are known. These diseases are characterised by early onset 
hyperglycaemia and are hence referred to as maturity-onset diabetes of the young (MODY) 
(117).
Diabetes affects approximately 285 million people world-wide and according to latest 
estimates diabetes prevalence will be 439 million (approximately 7.7%) in 2030 (118). In Finland, 
more than 10% of the adult population are estimated to have T2DM and only half of the 
affected individuals recognise that they have this condition (119, 120). 
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Table 2. Key adipokines and their functions (108, 109). 
Adipokine Function Levels
in
obesity  
adiponectin insulin sensitising, anti-atherogenic and anti-inflammatory 
AGT (angiotensinogen) involved in hypertension and AT growth  
apelin  insulin sensitizing and anti-atherogenic 
ANGPTL2 (angiopoietin-like 
protein 2) 
implicated in induction of insulin resistance, pro-
inflammatory  

CCL2 (CC-chemokine ligand 2), 
MCP-1 
acts as a receptor for several chemokines,  
potentially promotes glucose intolerance and insulin 
resistance, pro-inflammatory 

CXCL5 (CXC-chemokine ligand 5) interferes with insulin signaling, pro-inflammatory 
IL-6 role in obesity-induced insulin resistance controversial, 
pro-inflammatory  

IL-18 complex role in metabolism, pro-inflammatory  
leptin appetite control, pro-inflammatory  
lipocalin 2 implicated in induction of insulin resistance, pro-
inflammatory  

PAI1
(plasminogen activator inhibitor 1) 
physiological inhibitor of plasminogen activation 
NAMPT (nicotinamide phospho 
ribosyltransferase), visfatin 
potential regulator of insulin secretion, pro-inflammatory  
RBP4 (retinol-binding protein 4)  retinol transporter, potentially contributes to systemic 
insulin resistance, pro-inflammatory 

resistin promotion of insulin resistance in mice, pro-inflammatory  ? (116) 
SFRP5 (Secreted frizzled-related 
protein 5)  
suppressor of pro-inflammatory Wnt signalling 
TNF (tumour necrosis factor) pro-inflammatory, promotes insulin resistance by 
attenuating insulin signalling 

AT, adipose tissue; IL, interleukin 
Currently, the diagnosis of T2DM is based on plasma glucose values in the fasting state or after 
an oral glucose tolerance test (OGTT) performed with 75-g glucose load according to the 
following diagnosis criteria: 1) any casual plasma glucose 11.1 mmol/l accompanied with 
symptoms of hyperglycaemia, 2) fasting plasma glucose 7.0 mmol/l, or 3) 2-h plasma glucose 
11.1 mmol/l (117, 121). In the Finnish Diabetes Prevention Study (DPS), and hence in this 
study, however, the former WHO criteria (1985) for T2DM was applied with the higher 
diagnostic value of 7.8 mmol/l for fasting plasma glucose concentration (122). Since transition 
from normoglycaemia to T2DM is a gradual process, individuals with glucose levels above 
normal, but not meeting the criteria for diabetes, are considered pre-diabetic, and are defined 
according to the American Diabetes Association criteria as having impaired fasting glucose 
(IFG, fasting glucose levels 5.6-6.9. mmol/l) or impaired glucose tolerance (IGT, 2-h postload 
glucose 7.8-11.0 mmol/l) (123), whereas the European Diabetes Epidemiology Group sets the 
lower cut-off point for the definition of IFG to 6.1 mmol/l (124).  
2.6.2 Risk factors  
Overall,  the  risk  factors  of  T2DM  are  well  defined  and  include:  age,  BMI,  abdominal  obesity,  
lack of physical activity and family history of diabetes (117, 125, 126). In addition, a diet high in 
cereal fibre and polyunsaturated fat, and low in saturated fat, trans fat and glycaemic load 
associates with lower incidence of T2DM (127). Importantly, numerous well controlled 
intervention studies have demonstrated the efficacy of beneficial lifestyle changes in preventing 
or delaying development of T2DM in individuals with increased risk (81, 128-131). 
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2.6.3 Pathophysiology of T2DM 
Carefully orchestrated insulin secretion by pancreatic beta cells in response to subtle changes in 
blood glucose levels is a prerequisite for maintaining normal glucose homeostasis. The relative 
importance of beta cell function and insulin resistance in the pathophysiology of T2DM has 
been debated extensively for few decades. It is now clear, however, that these two sides are 
interconnected by a tightly regulated feedback system, and both beta cell dysfunction and 
insulin resistance of the target tissues are already present at the early phases of T2DM (132).  
Insulin  resistance  is  a  condition in  which tissues  exhibit  a  reduced response to  insulin.  The 
main functions  of  insulin  include glucose  uptake and storage in  skeletal  muscle,  inhibition of  
lipolysis  in  AT,  and  inhibition  of  endogenous  glucose  production  in  liver.  The  binding  of  
insulin to its receptor on the target cell membrane triggers a cascade of signalling events leading 
ultimately to the translocation of the main insulin responsive glucose transporter, GLUT4, from 
intracellular vesicles to cell membrane (133). Obesity, especially intra-abdominal fat 
accumulation, is a major determinant of insulin resistance (134), disrupting the insulin 
signalling pathway at multiple levels through alterations in the levels and activities of 
signalling molecules and transcription factors (135). In addition, factors such as age, exercise, 
diet and genetics influence insulin sensitivity (132).  
The relationship between insulin secretion and insulin sensitivity is best described as a 
hyperbolic function (136), and beta cell action should thus always be interpreted in the context 
of concomitant insulin sensitivity (132). The main regulator of insulin secretion is blood glucose. 
Glucose enters beta cell via a transporter molecule and results in increased ATP/ADP ratio and 
closure of ATP-sensitive potassium channels. This leads to depolarisation of the cell membrane 
and opening of voltage sensitive calcium channels. Eventually, the influx of calcium triggers 
exocytosis of insulin granules. This, however, is a simplified view and in reality insulin 
secretion is a complex process affected by multiple factors, such as the quality, quantity and the 
administration route of the secretagogue, gastrointestinal hormones, prevailing glucose 
concentration and the degree of insulin sensitivity (132). Moreover, two separate entities, 
namely  reduction  in  beta  cell  mass  and  function,  seem  to  be  involved  in  impaired  insulin  
secretion and development of hyperglycaemia (137).  
2.6.4 Measurement of insulin sensitivity and secretion 
The gold standard for measurement of insulin sensitivity is considered to be the euglycemic 
hyperinsulinemic clamp technique (138). However, this method is too laborious and time 
consuming to be used in large study populations, and does not evaluate insulin secretion. 
Intravenous glucose tolerance test (IVGTT) with frequent sampling in the beginning (FSIGT) 
allows measurement of insulin and glucose during the dynamic phase immediately following 
glucose injection. The main advantage of this method is that beta cells are stimulated with 
known glucose dose without confounding effects of incretins and gastrointestinal hormones 
(139). In addition, reasonably accurate estimates of beta cell function and insulin resistance can 
be obtained by using the OGTT, which is simple and more suitable for various clinical settings 
(140).
2.6.5 The cardiometabolic syndrome 
Metabolic syndrome refers to a clustering of metabolic disorders, such as hypertension, 
dyslipidemia, central obesity, insulin resistance, and hyperglycaemia, and it is associated with 
an  increased  risk  of  CVD  and  T2DM  (10,  141).  Several  definitions  of  the  metabolic  syndrome  
have been suggested (142), but its value as a CVD risk marker relative to individual risk factors 
or other risk scores has also been questioned (143, 144). Insulin resistance is the trait that 
connects all the components of the metabolic syndrome, and is causally involved in the 
development of CVD (133). Moreover, as discussed above, obesity is associated with systemic 
low-grade inflammation and dysregulated production of adipokines, both of which contribute 
significantly to development of CVD (109).  
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The molecular link between insulin resistance and increased atherosclerosis occurs through 
dysfunctional insulin signalling. The signaling cascade, leading to stimulation of glucose 
transport via GLUT4, is impaired in skeletal muscle of diabetic and obese individuals leading 
not only to decreased glucose uptake (133, 145), but also deficient production of nitric oxide 
(NO), which in turn is associated with endothelial dysfunction (146, 147). Moreover, insulin 
functions as a growth-factor promoting cell proliferation and differentiation via mitogen-
activated protein kinase pathway. This pathway remains sensitive to insulin, is excessively 
stimulated by compensatory hyperinsulinemia, and may contribute to accelerated 
atherosclerosis through vascular smooth muscle cell proliferation, and production of 
inflammatory cytokines (133, 148).  
2.6.6 Genetics of T2DM 
Although  environmental  factors  play  significant  role  in  aetiology  of  T2DM,  strong  genetic  
component is suggested by high concordance rate in monozygotic twins compared with 
dizygotic twins, increased disease risk for individuals with family history of the disease, and 
large variation of prevalence observed among ethnic groups living in similar environments 
(149-151). The lifetime risk of T2DM is approximately 40% for offspring of at least one affected 
parent (152) and the relative risk was reported to be 2.24 in first-degree, 1.36 in second-degree, 
and 1.14 in third degree relatives of T2DM patients (153). The highest prevalence rates of T2DM 
are seen in Pima Indians of Arizona and lowest in populations with European ancestors (154, 
155).
The heritability estimates of T2DM range from 26 to 75% (149, 150, 156). Evidence from twin 
studies suggests that both insulin sensitivity and insulin secretion have significant genetic 
component in nondiabetic individuals, but the former is more influenced by environmental 
factors (89). The heritability estimate for insulin secretion and insulin resistance are generally 
reported to range from 50 to 70%, and from 26 to 40%, respectively (89, 150, 157), and 
differential genetic architecture for these traits is suggested by meta-analyses (158).  
MODY
MODY  represents  a  group  of  monogenic  diabetes  disorders  occurring  in  young  adult  life.  
Studies  identifying  the  genes  for  MODY  have  been  successful  and  at  least  seven  different  
subtypes of MODY have been identified with distinct genetic, metabolic and clinical features 
(159). The majority of MODY genes are expressed in beta cells and are involved in beta cell 
development and glucose sensing (160). 
T2DM 
The genetic basis of common T2DM is polygenic, heterogeneous and still largely unknown. 
Currently, over forty confirmed susceptibility variants for T2DM have been identified, but these 
variants explain less than 10% of the heritability of T2DM (53, 161). These variants are 
distributed across the whole genome and mitochondrial DNA, and the majority of them are 
located within or near genes that are involved in beta cell development or function (161). Genes 
related to insulin resistance and related phenotypes are clearly underrepresented, and it has 
been suggested that T2DM emerges as a result of environmentally triggered insulin resistance 
in  individuals  whose  genetically  challenged  beta  cells  fail  to  respond  to  increasing  insulin  
demands (160). A list of the most replicated loci associated with T2DM is presented in Table 3. 
Common variation in genes associated with different MODY types have been studied for 
association with T2DM with the rationale being that variants with less radical effects could be 
associated with a milder disease phenotype and also be more common because of less stringent 
negative selection pressure (160). The candidate gene approach has yielded positive, albeit 
modest, associations with T2DM for many MODY genes (160). Interestingly, HNF1B, one of the 
MODY genes also named TCF2, was identified by a recent GWAS for T2DM (162). The MODY2 
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gene GCK,  encoding glucokinase,  has  been identified by four  GWASs for  fasting glucose  and 
glycated haemoglobin levels (158, 163-165). 
Mutations in the gene encoding wolframin (WFS1)  cause  Wolfram  syndrome,  which  is  a  
severe autosomal syndromic form of diabetes (160). Two GWASs have reported association of 
common WFS1 SNPs with T2DM (162, 166). The association between KCNJ11 gene, encoding 
islet ATP-sensitive potassium channel subunit Kir6.2, and T2DM was originally identified by 
candidate gene approach (167, 168), and subsequently confirmed by GWAS approach (69, 169-
172).
Table 3. The best confirmed loci for T2DM 
Nearest 
gene(s) 
Full name Putative function of the gene 
product/ connection with T2DM 
Reference
C2CD4A,
C2CD4B
C2 calcium-dependent domain 
containing 4A, 4B 
nuclear factors with a role in 
regulating genes that control cellular 
architecture 
(158, 177, 178)
CDC123,
CAMK1D 
cell division
cycle 123 homolog/ 
calcium, calmodulin- 
dependent protein kinase ID 
unclear, possibly cell cycle 
dysregulation 
(170, 178)
CDKAL1 CDK5 regulatory subunit 
associated protein 1-like 1 
unclear, possibly involved in first 
phase insulin secretion 
(69, 162, 166, 170-
172, 179-183) 
CDKN2A,
CDKN2B
cyclin-dependent kinase 
inhibitor 2A, 2B 
possibly involved in cell cycle 
regulation, beta cell mass 
(69, 162, 170-172,
180, 184) 
HHEX hematopoietically expressed 
homeobox 
transcription factor that may play a 
role in hematopoietic differentiation 
(69, 71, 162, 170-
172, 178, 180) 
HNF1A hepatocyte nuclear 
factor 1 homeobox A 
MODY3 gene (162, 184)
IGF2BP2 insulin-like growth factor 2 
mRNA binding protein 2 
functions by binding to the 5' UTR of 
the insulin-like growth factor 2 
(IGF2) mRNA and regulating IGF2 
translation 
(69, 162, 170-172,
180, 181, 184) 
JAZF1 juxtaposed
with another zinc finger gene 
1
unclear, transcriptional repressor of 
NR2C2 
(162, 170)
KCNJ11 potassium inwardly-rectifying 
channel, subfamily J, member 
11
insulin secretion (69, 169-171)
KCNQ1 subunit of voltage-gated 
potassium channel 
beta cell function (162, 180, 181, 184-
186)
PPARG peroxisome proliferator-
activated receptor gamma 
nuclear receptor involved in 
adipocyte differentation 
(69, 162, 170-172)
PTPRD protein tyrosine phosphatase,
receptor type, D 
unknown (185, 187)
SLC30A8 islet-specific zink membrane 
transporter ZnT8 
involved in insulin synthesis and 
secretion 
(69, 71, 158, 162,
166, 169, 171, 172, 
180, 183) 
TCF7L2 transcription factor 7-like 2 beta cell development and function,
plays a key role in the Wnt signaling 
pathway 
(69, 71, 162, 166,
169-172, 172, 180, 
182, 183, 188) 
TSPAN8/LGR5 tetraspanin 8/ leucine-rich
repeat containing G protein-
coupled receptor 5 
unknown (162, 170)
MODY, maturity onset diabetes of the young; UTR, untranslated region 
The strongest effect on T2DM risk described thus far is by the TCF7L2 gene. This gene was 
identified through linkage analysis followed by fine mapping, and the association has been 
subsequently replicated in several studies and meta-analyses (173, 174). A single copy of the 
TCF7L2 risk allele confers an approximately 40% increased risk, and two copies (carried by 
approximately 10% of individuals with European or African ancestors) an approximately 80% 
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increased risk (160). The exact role of TCF7L2 in T2DM susceptibility is not fully understood, 
but functional studies suggest that it may be involved in beta cell function (160, 175, 176). 
The PPARG gene encodes the peroxisome proliferator-activated receptor  and is a rare 
example of T2DM susceptibility genes affecting insulin sensitivity. The Pro12Ala polymorphism 
of this gene was originally identified and replicated consistently successfully by using 
candidate gene approach (67), and later on confirmed by GWAS approach (69, 162, 170-172).  
The recent discoveries in the field of T2DM genetics have already provided valuable insights 
into basic biological pathways underlying the disease, but have not yet led to clinical utility in 
risk prediction. Several studies have examined whether genetic factors improve the accuracy of 
predicting  future  T2DM  beyond  traditional  risk  factors,  and  most  have  concluded  that  the  
improvement in risk prediction is statistically significant, but clinically irrelevant (189, 190). 
Lyssenko et al. (189) found that 11 genetic variants previously associated with T2DM, improved 
slightly, but significantly, the prediction of T2DM compared with a model including only 
clinical risk factors. Interestingly the predictive value of genetic factors increased with longer 
duration of follow-up suggesting that the assessment of genetic risk factors may be more 
meaningful earlier in life (189). In the Finnish DPS participants lifestyle intervention reduced 
the T2DM incidence, whereas family history of T2DM or 19 previously identified risk SNPs did 
not have significant predictive value (191). 
2.7 CANDIDATE GENES IN THE PRESENT STUDY 
2.7.1 Adiponectin 
Adiponectin (also named Acrp30, AdipoQ, apM1, and GBP28) was described in the mid-1990s 
by four independent research groups (192-195). Adiponectin is the most abundant adipokine in 
circulation with concentration 0.05% (5-30μg/ml) of total serum protein (193). It is a secretory 
protein mainly produced by mature adipocytes (192), but is also detected in brown adipocytes, 
bone marrow, myocytes, cardiomyocytes, osteoblasts, salivary gland epithelial cells, placenta 
and wide range of fetal tissues (196-200). 
Human adiponectin comprises 244 amino acids, has a C-terminal globular domain and N-
terminal collagen-like domain, and resembles structurally the complement 1q and TNF family 
(193). Adiponectin is produced as a 32 kDa monomer, which is sequentially assembled into 
trimers, hexamers and high-molecular weight (HMW) multimers (12–18 mers) (193, 201). The 
HMW form is suggested to be biologically the most important isoform (202, 203), but its levels 
are highly correlated with total plasma adiponectin levels (204). Post-translational 
modifications, including hydroxylation, glycosylation and disulfide bond formation, are 
prerequisite for multimer formation and secretion of adiponectin (205). In addition, the 
proteolytic cleavage of the full-length protein generates globular form of adiponectin which 
circulates in low levels, but has been shown to be biologically active (206). The different 
adiponectin forms are likely to have at least partly distinct and possibly tissue-specific roles 
(201, 207). 
In 2003, two adiponectin receptors, ADIPOR1 and ADIPOR2, were characterised (208). These 
two receptors are structurally conserved, with 67% amino acid sequence identity, and highly 
conserved between species (208). They have seven transmembrane domains, but unlike G-
protein coupled receptors, they possess an intracellular N-terminus and extracellular C-
terminus (208). Interestingly, the HMW adiponectin has been suggested to act as a ligand for T-
cadherin (209), but the biological relevance of this receptor is currently poorly understood.
Adiponectin signalling pathway 
Adiponectin gene expression is up-regulated by multiple transcription factors involved in 
adipogenesis, such as PPAR, FoxO1, C/EBP, SREBP, and down-regulated by hypoxia, 
inflammation, endoplasmic reticulum (ER) stress, transcription repressors such as NFATs and 
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CREB, and pro-inflammatory factors such as TNF, IL-6 and IL-18 (205). Several ER associated 
proteins, such as Ero1-L, ERp44 and DsbA-L, play important roles in regulation of adiponectin 
multimerisation and secretion (205, 210). 
ADIPOR1 and ADIPOR2 serve as receptors for both globular and full-length forms of 
adiponectin, and mediate the increased AMP-activated protein kinase (AMPK), PPAR ligand 
activity, the fatty acid (FA) oxidation, and glucose uptake by adiponectin (208). Certain 
functional differences between ADIPOR1 and ADIPOR2 signalling pathways have been 
detected. ADIPOR1 has a high affinity for the globular adiponectin and low-affinity for the full-
length adiponectin, while ADIPOR2 has intermediate affinity for both globular and full-length 
adiponectin (208). Moreover, ADIPOR1 signalling leads to inhibition of gluconeogenesis and 
increased FFA oxidation through activation of the AMPK, whereas ADIPOR2 is involved in 
FFA oxidation and inhibition of oxidative stress and inflammation through PPAR activation 
(211).
The downstream signalling of adiponectin is not fully understood. In mammalian cells, the 
cytoplasmic N-terminal domain of ADIPOR1 interacts with APPL1 (adaptor protein, 
phosphotyrosine interaction, PH domain and leucine zipper containing 1) and this interaction is 
stimulated by adiponectin (212). APPL1 mediates the metabolic functions of adiponectin, but 
also functions in the insulin signalling pathway (213). Since the downregulation of T-cadherin 
leads to enhanced ADIPOR1/2 signalling, it has been proposed to function as adiponectin co-
receptor either competing for adiponectin binding or interfering with the downstream signaling 
(209).
Adiponectin in different physiological conditions 
The circadian variability (214) and the long-term within-person variability (215) of circulating 
adiponectin are low, but several genetic and non-genetic factors influence circulating 
adiponectin levels.  
Sexual dimorphism has been described for total and HMW adiponectin with women having 
higher concentrations than men, independent of body mass and fat distribution (201, 216). The 
explanation for gender differences is currently lacking, but it is possible that differences in 
estrogen and androgen levels are involved (216). Circulating levels of adiponectin are high at 
birth and fall gradually during the first decade of life (217, 218). In healthy adults, however, age 
correlates positively with adiponectin levels (216). 
Circulating adiponectin levels correlate negatively with BMI (219), most notably with central 
fat distribution (202, 216), and weight loss results in increase in adiponectin levels (220). 
Moreover, circulating adiponectin levels correlate more strongly with insulin resistance than 
with obesity (221), and although circulating adiponectin levels are generally decreased in 
obesity (219), metabolically healthy obese individuals have similar adiponectin levels to those 
observed in normal weight individuals (222). In addition, hypoadiponectinemia is observed in 
conditions, such as insulin resistance and T2DM (221, 223), dyslipidemia (224), and CVD (225). 
In contrast, high adiponectin levels are observed in type 1 diabetes (226) and anorexia nervosa 
(227). The causal relationship between adiponectin levels and insulin resistance, T2DM and 
CVD  in  human  is  currently  unclear.  A  recent  meta-analysis  of  13  prospective  studies  
demonstrated that high adiponectin levels are associated with decreased risk of T2DM (228), 
whereas for CVD the results are ambiguous (229). 
Factors affecting adiponectin levels in humans 
Several dietary factors have been reported to affect adiponectin levels. High glycaemic load was 
associated with low adiponectin concentrations in diabetic (230) and non-diabetic (231) men, 
and adherence to a Mediterrean-type diet was associated with higher adiponectin levels in 
diabetic  women  (232).  In  a  recent  isocaloric  cross-over  feeding  study,  a  diet  rich  in  
monounsaturated fat led to a higher increase of both HMW and total adiponectin than diets rich 
in carbohydrates or protein (233). In addition, several studies have consistently demonstrated 
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that moderate alcohol usage is associated with higher circulating adiponectin (231, 232). Acute 
exercise or endurance training do not seem to result in significant changes in circulating 
adiponectin levels when loss of AT and increase of lean mass is accounted for, and it seems 
more likely that some of the insulin sensitising effects of exercise are mediated by tissue-specific 
alterations in expression levels of adiponectin receptors (234). Finally, some existing drugs, such 
as statins, angiotensinogen converting enzyme inhibitors, thiazolidinediones and sulfonylureas, 
have been shown to increase and others, such as -adrenergic agonists, to decrease adiponectin 
concentrations in humans (210). 
Adiponectin  levels  are  also  largely  determined  by  genetic  factors,  only  part  of  which  has  
been identified thus far. The heritability estimates for circulating total and HMW adiponectin 
are generally high ranging from 30 to 70 % (203, 235-238). Association between circulating 
adiponectin levels and variants in the gene encoding adiponectin, ADIPOQ, have been reported 
by several candidate gene studies (203, 235, 238-241), and confirmed recently by GWASs (237, 
242-244). In addition, few other genetic loci associating with circulating adiponectin levels have 
been identified by GWASs. Wu et al. (242) reported that variation ADIPOQ and two other gene 
loci, CDH13 and KNG1, explained approximately 8 % of variability in adiponectin levels in 
Filipino mothers and offspring. Interestingly, association of CDH13 variation with adiponectin 
levels has also been observed in GWASs performed on European (237) and Korean (245) 
populations. CDH13,  located  on  chromosome  16,  encodes  T-cadherin,  which  is  a  receptor  for  
HMW forms of adiponectin (209).  
Expression of Adiponectin Receptors in Humans  
In humans, the genes for both adiponectin receptors (ADIPOR1 and ADIPOR2) are expressed in 
wide range of tissues including liver, pancreatic beta cells, skeletal muscle, AT, central nervous 
system, macrophages and atherosclerotic lesions (246-252). The exact roles of ADIPOR1 and 
ADIPOR2 are  not  currently  fully  understood and may be  diverse  and even opposing in  some 
tissues. Human studies regarding the link between expression levels of adiponectin receptors in 
various tissues and physiological conditions have been performed mainly at mRNA level and 
the results have been inconsistent.  
The AT mRNA expression levels of either or both receptors are reported to be decreased in 
obese and/or insulin resistant individuals in most (251, 253, 254), but not all (255) studies, and 
increase as a result of weight loss and physical activity (246, 251) .  
The expression levels of adiponectin receptors are higher in muscle than in AT (204). 
Civitarese et al. (248) reported that ADIPOR1/2 expression in skeletal muscle correlated 
positively  with  insulin  sensitivity  and  was  lower  in  individuals  with  family  history  of  T2DM  
than in those without family history, whereas others found no difference in muscle ADIPOR1/2
expression between T2DM patients and lean controls (256), or reported increased expression of 
both receptors in insulin resistance and T2DM (257).  
In the liver, the mRNA expression of both receptors was higher in obese insulin resistant 
individuals than in obese insulin sensitive subjects (258). Studies investigating adiponectin 
receptor expression in steatosis and non-alcoholic steatohepatitis have produced contradictory 
results as some have reported up-regulated (252, 258, 259) and others down-regulated (260, 261) 
expression levels.  
The expression of both receptors was increased in lymphocytes of anorectic patients 
compared to obese individuals (262). In monocytes of obese and T2DM patients the expression 
of ADIPOR1/2 was elevated at mRNA level, but decreased at protein level in comparison with 
normal weight controls (263). Similarly, suggesting separate transcriptional and translational 
regulation, ADIPOR1 and ADIPOR2 expression was decreased in monocytes of obese subjects 
with  coronary  artery  disease  (CAD)  compared  with  obese  controls  at  protein  level,  but  no  
difference was observed at the mRNA level (264).  
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Adiponectin pathway in mice 
In mice, injection of recombinant full-length adiponectin ameliorates insulin resistance (265, 
266) by suppressing hepatic gluconeogenesis (267). Moreover, a transgenic mouse model with 
3-fold elevated endogenous adiponectin levels displayed improved hepatic insulin sensitivity 
and increased lipid clearance (268). Interestingly, leptin-deficient (ob/ob) mice over-expressing 
adiponectin were morbidly obese, indicating even further expansion of AT compared with ob/ob
mice, but displayed a normal metabolic profile (269). Although the physiological significance of 
the globular adiponectin domain is unknown, acute administration of this cleavage product in 
mice increased FA oxidation by muscle, and daily administration of low dose resulted in weight 
loss (206). Another study demonstrated that chronic over-expression of globular adiponectin 
protected ApoE-deficient mice from atherosclerosis and ameliorated insulin resistance in ob/ob
mice (270).
Different strains of adiponectin-deficient mice demonstrate phenotypic variation with 
different degrees of insulin resistance, which is likely explained by differences in genetic 
background. Kubota et al. (271) reported that adiponectin KO-mice are insulin resistant and 
show increased neointimal formation, whereas others found that adiponectin KO-mice have 
relatively normal insulin sensitivity on standard diet, but are susceptible to diet-induced insulin 
resistance (272, 273). Unexpectedly, Ma et al. (274) found that beta oxidation was increased in 
muscle and liver of adiponectin-deficient mice and these mice had similar insulin sensitivity 
than their wild-type counterparts.  
In mice, AdipoR1 is expressed ubiquitously, most abundantly in skeletal muscle, whereas 
AdipoR2 is predominantly expressed in liver (208). The expression levels seem to be negatively 
regulated by insulin in its target tissues. In insulin resistant ob/ob mice, the expression levels 
were decreased in muscle and AT, whereas insulin-deficiency was associated with increased, 
and insulin replenishment with decreased, expression levels of both receptors (275). 
Adenovirus mediated expression of AdipoR1 and AdipoR2 in liver improved obesity-related 
insulin resistance and T2DM in leptin-receptor-deficient (db/db) mice through AMPK and 
PPAR pathways, respectively (211). The expression of AdipoR1 resulted in significant increase 
in AMPK activation and decreased expression of genes encoding enzymes involved in 
gluconeogenesis and lipogenesis, whereas expression of AdipoR2 increased PPAR and its 
target genes in liver of db/db mice (211).  
Mice deficient for both AdipoR1 and AdipoR2 are more glucose intolerant and insulin resistant 
than adiponectin-deficient mice, suggesting that the functions of the adiponectin receptors 
extend beyond the role of adiponectin itself (211). Unexpectedly, mice deficient for either 
AdipoR1 or AdipoR2 exhibited remarkably opposite phenotypes (276). Yamauchi et al. (211) 
reported that mice deficient for either adiponectin receptor had normal body weight, but were 
insulin resistant. However, in another study, AdipoR1-deficiency led to increased adiposity, 
through decreased energy expenditure, and decreased glucose tolerance (276). On the other 
hand, AdipoR2-deficient mice in this study were lean and resistant to high-fat diet induced 
weight gain, had lower liver TG, and showed improved glucose tolerance (276). Long-term 
high-fat feeding, however, seems to predispose AdipoR2-deficient mice to T2DM due to failure 
of beta cells to compensate for the moderate insulin resistance (277). 
Metabolic effects of adiponectin in its target tissues  
In addition to the well-documented insulin-sensitising and anti-inflammatory effects, 
adiponectin has diverse effects on numerous other physiological functions in different target 
tissues, such as protective role in carcinogenesis (278), and beneficial effects on reproduction 
and fertility (279). The key metabolic actions of adiponectin in target tissues are illustrated in 
Figure 1. 
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Figure 1. The metabolic and antiatherogenic effects of adiponectin in key target tissues. FA, fatty 
acid; CNS, central nervous system. 
Adiponectin improves insulin-mediated glucose uptake by skeletal muscle and suppresses 
hepatic glucose output (208, 267, 280). It also promotes FA oxidation and thus reduces the TG 
content of skeletal muscle and liver, and thus ameliorates insulin resistance (266, 270). In 
pancreatic beta cells, adiponectin stimulates insulin secretion (281) and may protect beta cells 
from cytokine- and FA-induced apoptosis (282). Moreover, adiponectin accumulates in the 
injured vascular wall (283), inhibits monocyte adhesion to endothelial cells (284), suppresses the 
smooth muscle cell proliferation (285), decreases monocyte to foam cell transformation (283), 
and stimulates directly the NO production by endothelial cells (286). The direct cardioprotective 
effects of adiponectin include regulation of cardiac injury through modulation of anti-
inflammatory and anti-apoptotic pathways, and inhibition of hypertrophic remodeling (287). 
Finally, adiponectin promotes clearance of apoptotic cells by macrophages, thereby restraining 
inflammatory reactions (98).  
In addition to the peripheral actions, adiponectin is also involved in central regulation of 
energy homeostasis (207). While the HMW form seems to associate closely with peripheral 
insulin sensitivity, the trimeric and hexameric forms play major role in hypothalamus were they 
act through ADIPOR1 and AMPK activation in modulating food intake and energy expenditure 
(207).
Since adiponectin has well established insulin-sensitising, anti-inflammatory and anti- 
atherogenic effects at least in animal models, the genes encoding adiponectin and its receptors 
are attractive and widely investigated candidate genes for complex human traits ranging from 
obesity and T2DM to cardiovascular diseases and common cancers.  
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ADIPOQ
Adiponectin is encoded by the ADIPOQ gene (previously named AMP1 or ACDC) at 
chromosomal locus 3q27. Genome-wide scans have linked this chromosomal region to 
susceptibility to T2DM and metabolic syndrome (288-290). An enormous number of candidate 
gene studies have examined the association of common genetic variations in ADIPOQ with a 
plethora of metabolic traits and various diseases. Most studies have been performed in 
underpowered case-control cohorts and have produced to some extent contradictory and 
inconsistent results. Nevertheless, findings overall suggest that variants in the ADIPOQ locus 
may contribute to the phenotypic variation in metabolic traits, circulating adiponectin levels 
and  predisposition  to  T2DM.  Only  few  studies  with  prospective  design  have  analysed  the  
association of ADIPOQ variants  with  the  risk  of  T2DM  and  these  studies  are  summarised  in  
Table 4. 
Table 4. The key ADIPOQ candidate gene studies with a prospective study design. 
Study design Study population No. of 
SNPs  
Results Ref
3-year prospective study in 
subjects from the Insulin 
Resistance Syndrome (DESIR) 
cohort
~4, 500 French
Caucasian 
4 3-year risk of becoming 
hyperglycemic was affected by 
rs17300539 and rs2241766 
(291)
3.3-year multicenter study 
(STOP-NIDDM) comparing the 
effect of acarbose with 
placebo on T2DM prevention,  
770 middle-aged 
overweight subjects 
2 rs2241766 and rs1501299 predicted
conversion from IGT to T2DM 
(292)
12-weeks clinical intervention
study with a caloric reduction 
of 300kcal/day 
294 nondiabetic/
overweight–obese 
Koreans 
3 rs1501299 was associated with 
different responses of circulating 
adiponectin and insulin resistance to 
mild weight loss 
(293)
5-year prospective study 262 Chinese
subjects with IGT  
10 rs2241766 was associated with 
persistent hyperglycaemia at 5 years 
(66)
OGTT at baseline and after 
three years 
550 subjects with 
increased risk of 
type 2 diabetes,  
2 rs17300539 and rs266729 
haplotypes were associated with 
serum adiponectin levels, T2DM risk 
and glucose tolerance 
(294)
15-year follow-up Healthy Caucasian
men (n=3, 012)  
4 rs2241766 was associated with 
T2DM risk, while two four-SNP 
haplotypes and rs1501299 increased 
T2DM risk in interaction with obesity 
(295)
three clinical examinations 
over a 7-year period 
837 French-
Caucasian subjects 
2 rs17300539 and rs266729 haplotype 
were associated with WHR changes 
and adiponectin levels  
(296)
28-year follow-up Participants in the 
Framingham 
Offspring Study (n = 
2543)
22 rs17300539, rs822387 and 
rs6773957: adiponectin levels 
rs17366743: diabetes incidence and 
mean fasting glucose over 28 years 
of follow-up  
No associations with other adiposity 
and metabolic phenotypes 
(241)
12-week dietary and physical 
activity intervention  
Individuals with IFG 
or newly diagnosed 
T2DM (n=363)
3 SNPs rs266729 and rs1501299 
modified the changes in serum 
adiponectin and HOMA-IR in 
response to intervention 
(297)
OGTT, oral glucose tolerance test ; IGT, impaired glucose tolerance; IFG, impaired fasting glucose, WHR, waist-to-hip ratio, 
HOMA-IR, homeostasis model assessment of insulin resistance 
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The most extensively studied of the common ADIPOQ variants are rs2241766 (often denoted as 
+45), a synonymous SNP located in exon 2, and rs1501299 (often denoted as +276), located in 
intron 2. These SNPs have been associated with circulating adiponectin levels (203, 235, 240, 
241, 298, 299), T2DM or related quantitative traits (66, 291-293, 297, 298, 300-302), and obesity 
(66, 298, 303-306) in various populations. Overall, however, the results vary and have not been 
replicated in some populations (235, 307).  
In addition, many association studies have focused on SNPs located in the ADIPOQ
promoter region, particularly on SNPs rs266729 (often denoted as -11374 or -11377), and 
rs17300539 (often denoted as -11391), which are frequently associated with adiposity (305, 305, 
308), T2DM (235, 309-311), insulin sensitivity (312), and serum adiponectin concentrations (235, 
240, 241, 299, 308, 309, 313). More recently, the association of ADIPOQ locus with circulating 
adiponectin levels has been confirmed by GWASs (237, 242-244), but the association with other 
metabolic traits remains inconclusive. 
Few association studies have focused on rare ADIPOQ variants, which may directly affect its 
ability to form multimers, and some of these variants have been associated with circulating 
adiponectin levels and T2DM (201, 314). Recently, Bowden et al. (315) used combined family-
based and association approach with exome sequencing to identify a rare ADIPOQ variant 
(G45R) that accounted for 17% of the variance in plasma adiponectin levels in the Hispanic-
American population, but was not observed in African-American or European-American 
populations.  
ADIPOR1 and ADIPOR2 
Human ADIPOR1 and ADIPOR2 genes are located at chromosomal loci 1p36.13-q41 and 
12p13.33, respectively (208). To date, the role of ADIPOR1 and ADIPOR2 sequence variations in 
metabolic traits related to obesity T2DM and cardiovascular risk factors have been the focus of 
several candidate gene association studies that have produced variable and inconclusive results 
summarised in Table 5.  
2.7.2 Alpha2B- adrenergic receptor 
Altogether three human 2-adrenergic receptor (AR) subtypes (A-C) have been identified that 
belong to the family of G-protein coupled receptors (336). 2-ARs mediate a wide variety of the 
physiological actions of the catecholamines, adrenaline and noradrenalin, including regulation 
of sympathetic tone, blood pressure, lipolysis and insulin secretion (337, 338). Often more than 
one subtype is involved in regulation of a particular physiological function with both opposing 
and parallel actions (339). All three subtypes are widely distributed in human tissues, including 
beta cells (340), where noradrenalin acts through 2-ARs to inhibit glucose stimulated insulin 
secretion (341). 
ADRA2B gene 
The ADRA2B gene, located in chromosome 2, encodes the 2B-AR (336). A common genetic 
variant (12Glu9) leading to the deletion/insertion of three glutamic acid residues (301-303) in a 
stretch of 16 acidic amino acids, located in the third intracellular loop, has a pronounced impact 
on receptor phosphorylation, and as a result impairs the agonist-promoted desensitation in vitro
(342, 343) and in vivo (344).
Genetic association studies have linked the 12Glu9 variant with various traits, such as long-
term body weight change (345), reduced basal metabolic rate in obese individuals (342), 
hypertension or blood pressure (346, 347) risk of sudden cardiac death and acute myocardial 
infarction (348), acute coronary events (349), silent myocardial ischemia (284), impaired 
endothelial function (350), autonomic nervous function (351), sympathetic nervous response 
during sustained handgrip exercise (352), emotional and traumatic memory (353, 354), and 
amygdala activity during processing of emotional events (355). 
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Interestingly, many studies have found gene-lifestyle-interactions regarding the 12Glu9 
variant. Men homozygous for the Glu9 allele were susceptible to hypertension, but only in 
stressful work environment (356). In the DPS population, physical activity decreased the risk of 
T2DM more in carriers of the Glu12 allele, whereas favourable dietary changes associated with 
greater risk reduction in Glu9 homozygotes (357). Ten-week strength training resulted in 
significant decrease in intramuscular fat in Glu9 carriers, but not in individuals with Glu12/12 
genotype (358). On the other hand, individuals with the Glu12/12 genotype benefited from a 12-
month resistance training more than Glu9 carriers, and sedentary individuals with the Glu12/12 
genotype were particularly vulnerable to adverse changes in body composition (359). Li et al.
(360) reported that individuals homozygous for the Glu9 allele, particularly those less 
physically active, had a more favourable anthropometric phenotype than individuals 
homozygous for the Glu12 allele.  
Table 5. Candidate gene studies focusing on the role of ADIPOR1 and ADIPOR2 variants in metabolic 
traits. 
Study population No. of 
SNPs 
ADIPOR
1 2 Main results Ref
990 black and 977 white women 19 27 no association with serum adiponectin concentration or
BMI 
(316)
CAD cases (n=40) and controls 
(n=28)
- 8 rs767870 was associated with CAD, IMT, FMD (317)
451 subjects with metabolic
syndrome and an additional 
replication population (n=1754 
cases and controls)  
3 3 ADIPOR1 rs10920533 was associated nominally with 
WC and HOMA-IR in interaction with plasma saturated 
FAs 
(318)
302 Finns and two replication 
cohorts (600 Swedish men, 3000 
Finns)
1 2 ADIPOR2 rs767870 were associated with liver fat 
content and its surrogate markers in three cohorts 
(319)
441 probands and siblings, and 
262 parents 
7 13 ADIPOR1 rs7539542 and ADIPOR2 rs12826079 were 
nominally associated with IS in whites;  
ADIPOR1 rs1342387 and rs7539542 were nominally 
associated with IS in African-Americans 
(312)
Korean T2DM patients (n=757) 
and controls (n=644) 
7 4 ADIPOR1 rs7572865 was associated with HOMA-IR and 
transcriptional activity 
ADIPOR2 -63442G>C and rs1044471 were associated 
with WC, no association with T2DM 
(320)
622 non-diabetic subjects from 
the Quebec Family Study  
2 2 ADIPOR1 3882T>C was associated with glucose and 
insulin metabolism variables; no association with 
circulating adiponectin 
(302)
567 Brazilian individuals of 
European (n=443) or African 
(n=124) ancestry 
2 - no association with T2DM or metabolic/anthropometric 
risk factors  
(321)
Russians T2D patients (n=129) 
and non-diabetic controls 
(n=117)
1 2 ADIPOR2 rs11061971 and rs16928751 were associated 
with T2DM 
(322)
cross-sectional population based 
study examining the prevalence 
of cardiovascular risk factors 
(n=700)
2 3 ADIPOR2 rs1029629 and rs1044471 were associated 
liver function in diabetics and circulating adiponectin in 
nondiabetics 
(323)
French-Canadians participating in 
the Québec Family Study 
(n=759)
2 2 no association with BMI;
ADIPOR1 rs1539355 and ADIPOR2 rs2058112 were 
associated with RQ, ADIPOR1 rs1539355 in interaction 
with ADIPOQ SNP was associated with overall and 
abdominal adiposity 
(306)
prospective, nested case-control 
study with 714 T2DM cases and 
1120 controls from Nurses’ 
Health Study cohort 
6 16 ADIPOR1 rs1139646 and haplotype were associated 
marginally with T2DM  
(324)
Table 5 continues 
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Table 5 continued 
population-based T2DM case–
control (n=2, 127) and 
population-based metabolic 
quantitative trait study (n=1, 
721)
9 15 no association with insulin and glucose 
metabolism, T2DM or BMI 
(325)
African-American adolescents 
(n=483)
7 - ADIPOR1 rs1342387 and haplotypes associated 
with HOMA-IR in the non-lean subset 
(326)
case-control study (n= 594) 
with Chinese people 
1 ADIPOR2 rs12342 associated with T2DM, FPG,
fasting TG, and BMI 
(327)
20 German subjects with 
metabolic syndrome 
3 ADIPOR2 rs16928751, +870C/A (Ile290Ile) and 
rs9805042 were associated with serum adiponectin 
levels and fasting TG 
(328)
2 populations of CAD-positive 
and -negative subjects with 
T2DM (n = 411 and n = 533) 
6 - 3’ haplotype was associated with CAD, lower 
mRNA levels in mononuclear cells and AT 
(329)
Mexican-Americans (N=439)
from the 
San Antonio Family Diabetes 
Study 
6 24 ADIPOR1 rs7539542 was associated with adiposity
14 ADIPOR2 SNPs associated with fasting TG 
(330)
T2DM case-control
study of 1498 Caucasian 
subjects and two replication 
cohorts (altogether n=2876) 
5 12 ADIPOR2 rs767870, rs35854772 and rs2286380 
were associated with T2DM 
(331)
502 nondiabetic Caucasians 1 ADIPOR1 rs6666089 was associated with IS 
dependent on adiposity 
(185)
502 nondiabetic Caucasians 6 7 ADIPOR1 rs6666089 and -1927 were associated 
with IS and liver fat 
(332)
Amish subjects with T2DM (n = 
137), IGT (n = 139), and NGT 
(n = 342) 
5 14 ADIPOR1 rs2275737 and rs1342387/+5843 
associated with T2DM, but not with with BMI; 5 
ADIPOR2 SNPs associated with T2DM 
(333)
192 diabetic and 192 non-
diabetic Japanese subjects  
14 24 no association with T2DM (334)
Northern Europeans and 
African-Americans with (n=192 
and n=269, respectively ) and 
without T2DM (n=192 and 
n=136, respectively) 
22 - no association with T2DM, IS or insulin secretion (335)
CAD,  coronary  artery  disease;  FA,  fatty  acid;  FMD,  flow  mediated  dilatation;  FPG,  fasting  plasma  glucose;  HOMA-IR,  
homeostasis model assessment of insulin resistance; IMT, intima-media thickness; IS, insulin sensitivity; RQ, respiratory 
quotient; TG, triglycerides; WC, waist circumference. 
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3 Aims of the Study 
The purpose of the present study was to investigate whether sequence variants of certain 
candidate genes, selected based on their role in metabolism, contribute to traits related to body 
size, T2DM and CVD in the Finnish Diabetes Prevention Study (DPS) population. The specific 
aims of the present study were: 
1. To examine the association of the 12Glu9 polymorphism in the gene encoding ADRAB2
with T2DM risk and related phenotypes. 
2. To determine whether genetic variations in the ADIPOQ gene are associated with serum 
levels of adiponectin, T2DM risk and body size. 
3. To investigate the association of genetic variations in the ADIPOR1 gene with body size 
and the risk of T2DM. 
4. To study the association between ADIPOR2 genetic variants and CVD and related risk 
factors.  
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4 Subjects and Methods 
4.1 STUDY POPULATIONS AND STUDY DESIGNS 
4.1.1 The Finnish Diabetes Prevention Study (Studies I-IV)
The DPS is a randomised and controlled longitudinal lifestyle intervention study carried out in 
five study clinics in Finland (Helsinki, Tampere, Turku, Kuopio and Oulu) during 1993-2000 
(129). The main aim of the study was to assess the effect of lifestyle modification on T2DM risk 
in overweight, middle-aged individuals with IGT. Glucose tolerance status was defined 
according to the WHO 1985 criteria (122): IGT was defined as fasting plasma glucose < 7.8 
mmol/l and a 2-h plasma glucose 7.8–11.0 mmol/l (OGTT, glucose load 75 g). The inclusion 
criteria of study participants were: BMI>25, age 40-64 years, and IGT based on the mean value 
of to OGTTs (361). The exclusion criteria were previous diagnosis of diabetes, vigorous exercise, 
glucose lowering treatments, and certain chronic diseases and metabolic conditions which 
could affect 6-year survival or interfere with glucose metabolism (361). Altogether 522 
participants were randomly allocated either into a control group (n=257) or into a diet and 
exercise intervention group (n=265) with randomisation stratified according to study clinic, sex 
and the mean value of two hour plasma glucose concentration in OGTT.  
Medical history was recorded and anthropometric and laboratory measurements were taken 
at baseline and at each annual follow-up visit. The subjects in the intervention group received 
individually tailored diet and exercise counselling (129, 362). The main goals of the intervention 
were: 1) 5-10% reduction in body weight, 2) reduction in the intake of total fat to  30% and 3) of 
saturated fat to  10% of daily energy intake, 4) increase of the intake of dietary fibre to at least 
15 g per 1000 kcal, and 5) moderate-to-vigorous exercise at least 30 minutes per day. The 
subjects in the control group received general information on the benefits of healthy diet, 
physical activity and weight reduction. All subjects underwent an OGTT at each annual visit 
and in the cases of new diagnosis of T2DM the OGTT was repeated within a week to confirm 
the diagnosis (361). The median length of the active intervention period was four years, ranging 
from 1 to 6 years. DNA samples were available from altogether 507 study participants.  
Cardiovascular mortality and morbidity data were collected after median follow-up of 10.2 
years (range 1-13 years) from the national Hospital Discharge Register and Causes of Death 
Register using the national personal identification number (363). The end-points during follow-
up were total mortality, and incident cardiovascular events (fatal and non-fatal), including 
acute coronary events, coronary heart disease, stroke and hypertensive disease.  
Significant differences between the groups were not observed in any baseline clinical 
characteristics (361). The baseline characteristics of DPS participants whose DNA sample was 
available are shown in Table 6. The study protocol was approved by Ethics Committee of the 
National Public Health Institute in Helsinki, Finland and written informed consent was 
received from all participants.  
4.1.2 The Genetics of obesity and insulin resistance study (Study IV)
Altogether, 75 overweight or obese (BMI 28-40 kg/m2) men and women (aged 40-70 years) were 
recruited  to  the  Genetics  of  obesity  and  insulin  resistance  study  (Genobin).  The  subjects  had  
impaired fasting glycemia (IFG: fasting plasma glucose concentration 5.6-7.0 mmol/l) or IGT, 
and fulfilled at least two criteria of metabolic syndrome according to the Adult Treatment Panel 
III Criteria (364) as modified by the American Heart Association (365): 1) WC >102 cm for men 
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and >88 cm for women, 2) fasting serum TG 1.7 mmol/l, 3) fasting serum HDL cholesterol <1.0 
mmol/l for men and <1.3 for women; blood pressure 130/80 mmHg. The baseline 
characteristics of the Genobin participants are presented in Table 6. The Ethics Committee of the 
District Hospital Region of Northern Savo approved the study plan. All participants 
volunteered for the study and gave their written informed consent.  
Table 6. Baseline characteristics of the DPS and Genobin study participants. 
DPS Genobin
N (male/female) 160/324 29/27
Age (y) 55.19±7.03 (484) 59.43±6.82 (56)
Weight (kg) 86.26±14.17 (484) 92.77±13.99 (56)
BMI (kg/m2) 31.23±4.51 (484) 32.72±2.86 (56)
Waist circumference (cm) 101.22±11.04 (482) 108.88±8.87 (56)
Fasting plasma glucose (mmol/L) 6.13±0.75 (484) 6.44±0.49 (56)
2-h plasma glucose (mmol/L) 8.88±1.49 (484) 7.42±2.15 (56)
Fasting serum insulin (mU/L) 14.73±7.46 (439) 11.96±7.29 (56)
2-h serum insulin (mU/L) 95.57±65.83 (436) 83.38±72.92 (56)
Serum total cholesterol (mmol/L) 5.61±0.93 (483) 5.16±0.98 (56)
Serum HDL cholesterol (mmol/L) 1.21±0.29 (483) 1.23±0.22 (56)
Serum LDL cholesterol (mmol/L) 3.62±0.84 (481) 3.37±0.91 (56)
Serum triglycerides (mmol/l) 1.73±0.78 (483) 1.66±0.84 (56)
Diastolic blood pressure (mmHg) 85.68±9.54 (479) 88.80±10.00 (56)
Systolic blod pressure (mmHg) 137.94±17.43 (479) 136.27±13.97 (56)
Data are mean±SD 
4.2 METHODS 
4.2.1 Anthropometric measurements (Studies I-IV)
Detailed methodologies for all measurements performed in the DPS have been described earlier 
(366). Weight and height were measured in light clothing, and BMI was calculated as kg/m2.
WC was measured midway between the lowest rib and iliac crest, and hip circumference over 
the great trochanters in a standing position. Sagittal and horizontal diameters were measured in 
supine position on a hard surface as a distance from the surface to the highest point of abdomen 
(sagittal) and the maximal width of the abdomen (horizontal) at the level of iliac crest. The 
three-year weight change (Study I) was calculated as the difference between baseline weight and 
weight at the three-year examination or last available measurement. 
4.2.2 Biochemical measurements 
Two hour OGTT  
In the entire DPS population, a two hour OGTT was performed after a 12 hour fast to determine 
glucose tolerance status at baseline and annually. Samples for glucose and insulin 
determinations were drawn before, and 30 and 120 minutes after a 75 g glucose dose. Plasma 
glucose was measured locally by standard methods, and the measurements were standardised 
by central laboratory in Helsinki (129). Serum insulin was determined with radioimmunoassay 
(Pharmacia, Uppsala, Sweden).  
Blood lipid measurements 
Serum total cholesterol, HDL cholesterol and TG were analysed by using an enzymatic method 
(CHOD-PAP, Boehringer Mannheim, Germany). The Friedewald formula was used to calculate 
LDL cholesterol concentration (367). 
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Frequently sampled intravenous glucose tolerance test (Study I) 
In the Kuopio study clinic, an insulin-modified FSIGT was performed at baseline (368). In total 
83 DPS participants with available genetic data underwent the FSIGT. After drawing the fasting 
sample, a dose of 300 mg/kg of glucose was administered, as a 50% solution over 1.5 minutes, 
through a catheter inserted into the antecubital vein following infusion of 0.9% NaCl solution. 
After 20 minutes, a 0.03 U/kg bolus of insulin vas injected. Venous blood samples were collected 
before the glucose load (-5 min and 0 min) and 23 times after the glucose load. Plasma glucose 
concentration was analysed by a glucose oxidase method (Glucose Auto & Stat, Model GA-11, 
Daiichi, Kyoto, Japan) and insulin by radioimmunoassay method (Phadaseph Isulin RIA 100; 
Pharmacia Diagnostica, Uppsala, Sweden). The insulin sensitivity index (SI) was calculated 
using the MINMOD program (369). The acute insulin response (AIR) was calculated as the area 
under the curve above the baseline level from 0 to 10 min after the glucose load. The disposition 
index (DI) was calculated as a product of AIR and SI (136).  
Serum adiponectin measurements (Study II) 
Fasting serum adiponectin levels were measured using an enzyme-linked immunosorbent 
assay (B-Bridge International, Inc., CA, USA), on whole plasma samples stored at –80°C. The 
intra-assay and inter-assay coefficients of variation were 5.5–7.9% and 6.5%, respectively. 
Samples for adiponectin measurements were only available from subset of participants from 
three study clinics (n=243 at baseline, and n=209 at 4-year examination). In altogether 190 
subjects both baseline and year four serum adiponectin concentrations were measured.  
4.2.3 SNP Selection and genotyping  
In Study I, the ADRA2B 12Glu9 variant was selected as a candidate polymorphism for T2DM 
based on previous findings and functional effects of the variant. In Studies II and IV, the 
tagSNPs with minimum minor allele frequency of 5% were selected based on the genotype data 
of the Hapmap CEU (Utah residents with ancestry from Northern and Western Europe) 
population (13) by using the Tagger algorithm (370). In Study II, the ADIPOQ SNPs rs2241766 
and rs1501299, were selected based on previous literature and were forced into the tagSNP 
selection. In Study II, the ten SNPs selected for genotyping covered 73% of the common 
variation within ADIPOQ region with r2  0.8. In Study IV, the eight ADIPOR2 SNPs were based 
solely on the HapMap data to capture 63% of common variants within the ADIPOR2 locus with 
r2  0.8. In Study III,  the  seven  SNPs  were  selected  both  on  basis  of  previous  studies  and  the  
HapMap data (13). 
Genomic  DNA  was  isolated  from  peripheral  blood  leucocytes  by  the  Puregene®  DNA  
purification kit (Gentra Systems, Inc. Minneapolis, USA). The genotyping methods used in this 
work  vary  reflecting  the  technical  developments  in  the  field.  In  Study I, the ADRA2B 12Glu9 
variant was detected by a combination of PCR and fragment length analysis by gel 
electrophoresis. The ADIPOQ SNPs rs2241766 and rs1501299 (Study II) were genotyped using 
PCR followed by SNaPshot ddNTP Primer Extension Kit technique (ABI Prism; Applied 
Biosystems) as described earlier (292). ADIPOQ rs17366568 (Study II), ADIPOR1 SNPs rs2275738 
and rs2275738 (Study II) were genotyped using PCR-RFLP method by using MseI, MboII and 
MSlI restriction endonucleases, respectively. Other SNPs were genotyped with TaqMan Allelic 
Discrimination  assays  according  to  manufacturer’s  instructions  by  using  the  ABI  PRISM  7000  
sequence detector (Applied Biosystems, Foster City, CA). For a subset of randomly selected 
samples (6.3%) genotyping was repeated in order to calculate success rate.
The total number of DPS participants included in each association study varies to some 
extent due to availability of DNA samples at each time point and the permission given by the 
participants for use of their samples in genetic analyses: n=506 in Study I, n=507 in Study II and
Study III, and n=484 in Study IV .
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4.2.4 Gene expression analysis (Study IV)
Collection of peripheral blood mononuclear cells (PBMCs) and AT samples  
In the Genobin study, PBMCs were isolated according to the manufacturer’s instructions from 
anticoagulated peripheral blood by using Lymphoprep reagent (Axis-Shield, Oslo, Norway). 
AT biopsies were taken by aspiration with a syringe from the subcutaneous abdominal AT 
under local anesthesia (Lidocaine 10mg/ml without epinephrine). The AT samples for the RNA 
extraction were treated with RNA later according to manufacturer’s instructions (Ambion, 
Austin,  TX,  USA)  and  stored  at  -80  C. Altogether, 56 baseline PBMC and AT samples with 
genotype data were available for subsequent mRNA expression analyses.  
RNA extraction and quantitative real-time PCR 
Total RNA from AT samples was extracted using the TRIzol method (Invitrogen, Carlsbad, CA, 
USA, and Qiagen, Valencia, CA, USA) following further purification with RNeasy Mini Kit 
(Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. Total RNA from 
PBMS samples was isolated with RNeasy Mini Kit according to the manufacturer’s instructions. 
The integrity of RNA sample was assessed using gel electrophoresis and the RNA concentration 
and  the  A260/A280 ratio were measured using NanoDrop spectrophotometer (Nanodrop 
Technologies, Wilmington, DE) with acceptable ratio being 1.9-2.1. RNA was reverse 
transcribed into cDNA by using High-Capacity cDNA Archive Kit (Applied Biosystems, Foster 
City, CA, USA).  
Quantitative real-time PCR was performed as triplets with ready-made assays based on 
TaqMan® chemistry and analysed with ABI Prism 7500 SDS software (Applied biosystems). 
Each reaction comprised 6 ng cDNA, 1X Assay Mix, and 1X Taqman Universal PCR Master Mix 
(Applied biosystems). On each plate, a standard curve with five concentrations (0.5, 1.5, 6, 18, 
and 36 ng/μl) and calibrator (6 ng/μl) were included to determine the relative quantity of cDNA 
in each sample by using the methods described in ABI Prism User Bulletin no. 2. The quantities 
on each plate were first corrected by the calibrator and the relative amount per plate was 
corrected  with  the  corresponding  values  of  endogenous  control.  The  expression  of  
glyceraldehydes-3-phosphate dehydrogenase and cyclophilin A1 were used as an endogenous 
controls for normalising gene expression in PBMCs and AT, respectively.
4.2.5 Statistical analyses 
The pairwise LD between SNPs was evaluated with Haploview software (371). In Study III, the 
haplotype analyses were performed with THESIAS programme version 3 (372). The compliance 
of genotype frequencies with Hardy–Weinberg equilibrium (HWE) was tested with the chi-
square test.  
Otherwise, the statistical analyses were performed with SPSS for Windows (SPSS Inc, 
Chicago, IL, USA) version 11.0.1. (Studies I and III) or 14.0 (Studies II and IV). Data are presented 
as mean ± SD or as median (interquartile range), unless otherwise indicated. Normality of 
variable distributions was tested with the Kolmogorov-Smirnov test with Lilliefors correction or 
by plotting the residuals of each statistical test. Appropriate variable transformations were used 
to improve normality when necessary. Homogeneity of variances was tested using Levene’s 
test.  
In Study I,  the  relationship  between  insulin  secretion  and  insulin  sensitivity  for  each  
genotype was explored by fitting an exponential curve and calculating coefficients of 
determination. In all studies, the distribution of genotypes between the study groups was 
examined by chi-square test. Genotype differences in continuous baseline variables were 
analysed with the general linear model (GLM) univariate analysis of variance (ANOVA) with 
appropriate adjustments. Kruskal-Wallis test was used instead of ANOVA for variables that 
failed to meet normality assumptions. Longitudinal data was examined by using GLM for 
repeated measurements (Study III) or linear mixed models analysis (Study II) with appropriate 
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covariates. The significance of differences in the three-year diabetes incidence between 
genotypes was analysed by the chi-square test (Studies I and III). Logistic regression (Study I) or 
Cox regression (Studies II-IV) analysis with appropriate covariates were used to assess whether 
genotypes predicted the development of T2DM. In Study IV, the association of ADIPOR2 SNPs 
with cardiovascular risk was analysed with Cox regression with appropriate covariates.  
The  genetic  analyses  were  performed  by  comparing  all  three  genotype  groups  (additive  
inheritance model; used in all studies), by comparing the minor allele carriers to those 
homozygous for the major allele (dominant inheritance model; Studies II and IV)  or  by  
comparing the major allele carriers with those homozygous for the minor allele (recessive 
inheritance model; Study II). Analyses involving longitudinal data were performed separately in 
both  DPS  study  groups.  Moreover,  subgroup  analyses  were  performed  when  a  significant  
interaction was found between genotype and gender, genotype and study group, or genotype 
and WC. A p-value of <0.05 was considered to be statistically significant. Correction for 
multiple hypotheses testing with the false discovery rate (FDR) method was performed using 
Q-value software (373) for single SNP analyses in Studies II and IV. 0 was estimated with 
bootstrap method, with a 	 range from 0 to 0.9 by 0.05. 
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5 Results
This thesis comprises a series of candidate gene studies performed in the participants of the 
DPS (Studies I-IV). In addition, allele-specific mRNA expression was analysed in AT and PBMC 
samples  derived  from  Genobin  study  participants  (Study IV).  With  the  varying  number  of  
variants analysed per each of the four candidate genes, significant associations were found 
between several variants and various quantitative traits or disease risks. In this results part, the 
genetic associations are presented so that all variants associating with given or related 
phenotypes are considered in the same section.
5.1 GENOTYPE FREQUENCIES 
The genotype counts and minor allele frequencies of ADRAB2, ADIPOQ, ADIPOR1 and 
ADIPOR2 gene polymorphisms are  shown in  Table  7  with  the  minor  allele  frequencies  in  the  
HapMap CEU reference population (13). All SNPs except the ADIPOQ SNP rs16861210 and the 
ADIPOR2 SNP rs11061946 were in HWE (p>0.05). Since the q-values were high for both 
analyses (q=0.683 and q=0.377, respectively), these SNPs were included in subsequent analyses. 
The pairwise LD between genotyped ADIPOQ, ADIPOR1 and ADIPOR2 SNPs in the DPS study 
population are presented in Figures 2-4. 
Figure  2.  Schematic  presentation  of  the  ADIPOQ  (Study  II)  gene  indicating  the  locations  of  the  analysed  
variants, haploblocks and the pairwise LD (r2). 
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Figure 3. Schematic presentation of the ADIPOR1 (Study III) gene indicating the locations of the analysed 
variants, haploblocks and the pairwise LD (r2). 
Figure  4.  Schematic  presentation  of  the  ADIPOR2  (Study  IV)  gene  indicating  the  locations  of  the  analysed  
variants, haploblocks and the pairwise LD (r2). 
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Table 7. Genotype counts and allele frequencies of the ADRA2B, ADIPOQ, ADIPOR1 and ADIPOR2 variants 
studied in the DPS population. 
SNP rs-identifier 
(major/minor 
allele) 
Genotype 
(count) 
Location within 
gene 
MAF in DPS MAF in 
HapMap CEU  
0 1 2
ADRA2B Glu12/9 145 257 104 Glu9 0.459 -
ADIPOQ rs266729 (C/G) 219 240 48 5’ promoter region G 0.331 G 0.300 
rs16861205 (G/A) 337 151 19 Intron 1 A 0.186 A 0.084 
rs16861210 (G/A) 471 33 3 Intron 1 A 0.038 A 0.095 
rs17366568 (G/A) 371 122 14 Intron 1 A 0.148 A 0.119 
rs2241766 (T/G) 460 45 2 Exon 2 G 0.048 -
rs1501299 (G/T) 234 220 53 Intron 2 T 0.321 T 0.279 
rs3821799 (C/T) 149 255 103 Intron 2 T 0.455 T 0.438 
rs17366743 (T/C) 468 39 - Exon 3 C 0.038 C 0.075 
rs6773957 (G/A) 206 233 68 3’ UTR A 0.364 A 0.376 
rs2082940 (C/T) 466 39 2 3’ UTR T 0.042 T 0.102 
ADIPOR1 rs10920534 (C/T) 263 184 32 Intron 1 T 0.259 -
rs2275738 (G/A) 167 234 106 Intron 1 A 0.440 A 0.438 
rs12045862 (C/T) 246 214 47 Intron 2 T 0.304 T 0.215 
rs1342387 (G/A) 139 224 116 Intron 3 A 0.477 T 0.459 
rs7539542 (C/G) 222 236 49 3’ UTR G 0.329 G 0.289 
ADIPOR2 rs10848554 (G/C) 392 107 8 5’ promoter region C 0.121 C 0.138 
rs11061937 (T/C) 225 221 61 Intron 1 C 0.338 C 0.304 
rs11061946 (C/T) 451 51 5 Intron 1 T 0.060 T 0.080
rs1058322 (C/T) 244 213 50 Intron 1 T 0.309 T 0.285 
rs11061973 (G/A) 424 78 5 Intron 2 A 0.087 A 0.162 
rs4766415 (A/T) 137 263 107 Intron 2 T 0.470 T 0.487 
rs16928751 (G/A) 398 104 5 Exon 7 A 0.112 A 0.115 
rs1044471 (C/T) 143 254 110 3’ UTR T 0.467 T 0.478 
MAF, minor allele frequency; UTR, untranslated region 
5.2 ASSOCIATIONS WITH BODY SIZE 
5.2.1 ADIPOQ SNPs (Study II)
The ADIPOQ variations rs266729, rs16861205, rs1501299, rs3821799 and rs6773957 were 
associated with baseline body weight and BMI when adjusted for age and sex. The p-values for 
all  SNPs  are  presented  in  –log10 scale in Figure 5. The rs266729 G, the rs16861205 G, the 
rs1501299 G, the rs3821799 C, and the rs6773957 G allele associated dose-dependently with 
higher baseline body weight (Study II: Table 3). For rs266729 a significant sex–genotype 
interaction was found for weight and significant differences were observed in women.  
The same four SNPs were associated with the four-year follow-up measurements of weight 
in additive inheritance model (rs16861205: p=0.028/q=0.049, rs1501299:p=0.041/q=0.049, 
rs3821799: p=0.002/q=0.049, and rs6773957: p=0.045/q=0.049) and the associations were even 
stronger when the dominant inheritance model was used (rs16861205: p=0.008/q=0.049, 
rs1501299: p=0.014/0.049, rs3821799: p=0.001/q=0.049, and rs6773957: p=0.014/q=0.049). For 
rs266729, significant differences were only observed in women (p=0.007/q=0.038 for the 
dominant inheritance model, and p=0.027/q=0.309 for sex–genotype interaction). Similar 
genotype associations were found for BMI. The longitudinal body weight and BMI data are 
shown for rs3821799 in Figure 6. 
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Figure  5.  Association  of  ADIPOQ  SNPs  with  baseline  body  weight  and  BMI  (Study  II).  The  p-values  are  for  
ANOVA adjusted  for  age  and  sex,  and  are  presented  on  –log10 scale. Points above the line indicate p-values 
below the threshold of p<0.05. Black symbols, body weight; open symbols, BMI; Squares, additive inheritance 
model; triangles, dominant inheritance model.  
Figure 6. Body weight (A) and BMI (B) from baseline to year 4 according to ADIPOQ SNP rs3821799 (Study II). 
Data are mean±SEM; p-values for dominant inheritance model are adjusted for age, sex and study group. 
In the multiple SNP model including rs266729, rs16861205, rs1501299, rs3821799 and rs6773957, 
a trend for significant association with baseline body weight was observed for rs3821799 
(p=0.063). Following the removal of the three least significant SNPs rs3821799 (p=0.007) 
remained significantly associated with baseline body weight. 
5.2.2 ADIPOR1 SNPs (Study III)
ADIPOR1 SNPs rs10920534, rs22757538 and rs1342387 were significantly associated with 
multiple anthropometric measurements, such as body weight, height, BMI, WC, hip 
circumference, WHR, sagittal diameter, and horizontal diameter either in all individuals or in 
men and women separately. The rs10920534 TT, the rs22757538 GG, and the rs1342387 GG 
genotypes were associated with larger body size. In addition, carriers of the rs12045862 T allele 
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were taller compared with those with the CC genotype. Figure 7 presents the p-values (on a – 
log10 scale) for ADIPOR1 SNPs for all DPS participants and for men and women separately.  
Figure 7. Association of ADIPOR1 SNPs with various baseline body size measures in men (A) and women (B) 
(Study  III).  The  p-values  are  from  Kruskal-Wallis  test  or  ANOVA  adjusted  for  age  and  sex  (in  all),  for  
comparison among all three genotype groups. Points above the line indicate p-values below the threshold of 
p<0.05.  
Genotype differences in body size measures were further reinforced by analysing the 
longitudinal data from baseline to year three. In the entire study population, significant 
differences were seen according to rs10920534 (Study III: Figure 2), rs2275738 and rs134287 in 
body weight (p=0.002, p=0.001 and p=0.007, respectively) and WC (p=0.001, p=0.003 and 
p=0.012, respectively) when adjusted for age and sex. When the follow-up period was extended 
to year four and analysed using the linear mixed models analysis (adjusted for age, sex and 
study group), genotype differences remained significant for all three SNPs, as shown for 
rs10920534 in Figure 8. 
Figure  8.  Body  weight  (A)  and  waist  (B)  circumference  from  baseline  to  year  4  according  to  ADIPOR1  
rs10920534 (Study III). Data are mean±SEM; p-values for additive inheritance model are adjusted for age, sex 
and study group.  
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In addition to single SNP analyses, we examined the covariate adjusted effects of five-marker 
haplotypes on baseline body size measurements by comparing all other haplotypes with 
frequency over 0.03 with the most frequent haplotype (Study III: Table 3). The  results  of  the  
haplotype analyses supported the results of single SNP analyses by showing associations 
between large body size measurements and those haplotypes that harboured alleles associated 
with larger body size.  
5.3 ASSOCIATION OF ADIPOQ SNPS WITH SERUM ADIPONECTIN LEVELS 
(STUDY II)
In a subgroup of DPS study participants,  three ADIPOQ SNPs associated with baseline serum 
adiponectin levels, adjusted for age, sex and baseline WHR (Figure 9 and Table 5 in Study II). 
Lower baseline serum adiponectin concentrations were associated with the rs16861210 G allele, 
the rs17366568 A allele and the rs6773957 G allele. Moreover, the rs2241766 TT genotype and 
the rs2082940 CC genotype showed a trend for association with lower levels. In the multiple 
SNP model including rs16861210, rs17366568, rs6773957 and either rs2241766 or rs2082940, the 
first two SNPs remained significantly associated with baseline adiponectin levels (p=0.012 and 
p=0.003, respectively). 
Figure 9. Baseline serum adiponectin levels according to ADIPOQ SNPs (Study II): rs16861210, rs17366568, 
rs6773957, and rs2241766/rs2082940 (with identical results). P-values for the dominant inheritance model, 
adjusted for age, sex and baseline WHR.  
5.4 ASSOCIATIONS WITH INSULIN AND GLUCOSE METABOLISM, AND THE 
RISK OF T2DM 
Altogether 72 individuals for whom genotype data were available converted from IGT to T2DM 
(21 in the intervention group and 51 in the control group) during the three-year study period, 
with 58% relative risk reduction in the lifestyle intervention group (129, 362). During the 
extended follow-up of 0-11 (median 7) years number of individuals that converted to T2DM 
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was 184 (74 in the intervention group and 110 in the control group), with 43% relative risk 
reduction in the lifestyle intervention group (81). 
Genetic variants in ADRA2B, ADIPOQ and ADIPOR2 associated with the risk of T2DM and 
the results from extended follow-up period are presented for these variants in Table 8. There 
were no significant differences in genotype associations between the study groups and the data 
is presented for the entire DPS population.  
5.4.1 ADRA2B 12Glu9 polymorphism and the risk of T2DM (Study I)
A statistically significant interaction between study group ADRA2B 12Glu9 variant was 
observed for the risk of T2DM (p=0.003, adjusted for age, sex, WC, three-year weight change, 
study group and fasting plasma glucose). When the study groups were analysed separately, 
individuals carrying the Glu9 allele had increased risk of developing T2DM compared with 
those with the Glu12/12 genotype in the control group (OR=2.68, 95% CI 1.02-7.09, p=0.047 for 
Glu12/9 and OR=5.17, 95% CI 1.76-15.21, p=0.003 for the Glu9/Glu9 genotype). On the contrary, 
the  Glu9/9  genotype  was  associated  with  a  lower  risk  of  T2DM  in  the  intervention  group  
(OR=0.09, 95% CI 0.01-0.99, p=0.049).  
Table 8. Summary of the hazard ratios for ADRA2B, ADIPOQ and ADIPOR2 variants associating with 
the risk of T2DM in DPS. 
Gene Variant Genotype HRR, (95% CI), p/qa HRR, 95% CI, p/qb
ADRA2B 12Glu9 Glu12/12 (139) 1 1
Glu12/9 (244) 1.460, (1.024-2.081), 0.036 c 1.446,
(1.021-2.049),  
 0.038c
Glu9/9 (98) 1.243, (0.801-1.929), 0.331 c
ADIPOQ rs266729 CC (219) 1 1
CG (240) 0.695, (0.513-0.942), 0.019/0.203 0.682
(0.510-0.912), 0.010/0.203 GG (48) 0.615, (0.350-1.081), 0.091/0.330 
rs2241766 TT (460) 1 1
TG (45) 1.521, (0.944-2.452), 0.085/0.330 1.634
(1.035-2.579), 0.035/0.216 GG (2) 5.448, (1.329-22.333), 0.019/0.203 
rs2082940 CC (466) 1 1
CT (39) 1.383, (0.812-2.357), 0.233/0.668 1.518
(0.918-2.512), 0.104/0.334 TT (2) 5.368, (1.310-21.997), 0.020/0.203 
ADIPOR2 rs11061946 CC (428) 1 1
CT (49) 0.767, (0.449-1.309), 0.331/0.802 0.926,
0.572-1.1499,  
0.753/0.918 
TT(5) 4.263, (1.528-11.893), 0.006/ 0.514 
rs11061973 GG (401) 1
GA (76) 1.044, (0.700-1.558), 0.831/0.934 1.149, 0.786-1.681, 0.474/0.885 
AA (5) 4.425, (1.585-12.352), 0.005/0.514 
aAdditive inheritance model, adjusted for age, sex, baseline fasting glucose concentration, baseline WHR and study group; 
bDominant inheritance model, adjusted for age, sex, baseline fasting glucose concentration, baseline WHR and study group; c
FDR not applied 
A trend for interaction between 12Glu9 and baseline WC was observed for T2DM incidence 
(p=0.052). Subsequently, men and women were categorised according to the cut-off values of 
102 cm for men and 88 cm (102) and the association between 12Glu9 and T2DM incidence was 
analysed in these groups separately. In the high WC group, the Glu9 allele was dose-
dependently associated with a higher incidence of T2DM (p=0.011, for comparison among three 
genotype groups), whereas in the low WC group the Glu9 allele was associated with a lower 
incidence of T2DM (p=0.002, for comparison among three genotype groups) (Study I: Figure 1). 
The Glu12/9 and the Glu9/9 genotypes associated with a higher risk of T2DM (OR=2.30, 95% CI, 
p=0.063, and OR=3.80, 95% CI 1.41-10.26, p=0.008, respectively) when compared with the Glu 
12/12 genotype in the high WC group. In the low WC group, the Glu12/9 genotype 
demonstrated a trend for lower T2DM risk in comparison with the Glu12/12 genotype, but 
statistical significance was not reached by using the additive inheritance model.  
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When follow-up was extended to mean 6.4 years and analysis method was changed to Cox 
regression, to match Studies II-IV, a significant (at p<0.05 level) difference in risk of T2DM was 
still seen according to 12Glu9 genotype in the whole DPS population (Table 8) with the 
dominant inheritance model. The genotype-study group interaction was no longer significant, 
and when the study groups were analysed separately the association between ADRA2B
genotype and T2DM risk was not significant in either group. Interestingly, with the extended 
follow-up, a significant interaction between genotype and baseline WC was still observed 
(p=0.033, for the dominant inheritance model). In the low WC group, the Glu9 allele carriers 
had lower (HR=0.38, 95% CI 0.16-0.92, p=0.032) and in the high WC group higher (HR=1.83, 95% 
CI 1.22-2.76, p=0.003) risk of T2DM compared with individuals with the Glu12/12 genotype. 
5.4.2 Association of ADRA2B 12Glu9 with insulin secretion (Study I)
In a subpopulation of study participants (n=83), a frequently sampled intravenous glucose 
tolerance test (FSIGT) was performed at baseline. In this subgroup the, Glu9 allele was 
associated dose-dependently with low AIR and DI (p=0.004 and p=0.003, respectively, adjusted 
for age, sex, and BMI) (Figure 10). Moreover the exponential relationship between AIR and SI 
was only seen individuals with the Glu12/12 genotype (r2=0.223, p=0.006), but not in individuals 
carrying the Glu9 allele (Study I: Figure 2). 
Figure 10. Baseline AIR (A) and DI (B) according to ADRA2B 12Glu9 genotype (Study I). Values are medians 
(interquartile ranges). The p-values are for ANOVA comparison among all three genotype groups, adjusted for 
age, sex and BMI. 
5.4.3 ADIPOQ SNPs and the risk of T2DM (Study II)
The ADIPOQ SNP rs266729 G allele associated with a decreased risk for conversion from IGT to 
T2DM (Table 8). In addition, the homozygous minor allele carriers (n=2) of rs2241766 and 
rs2082940 (GG and TT, respectively) had increased risk of developing T2DM (Table 8). In a 
multiple-SNP model including all three SNPs, only rs266729 associated with T2DM risk 
(HR=0.693, 95% CI 0.518-0.928, p=0.014 fot the G allele carriers compared with individuals with 
the CC genotype). 
5.4.4 ADIPOR1 SNPs and baseline insulin concentrations (Study III)
Three ADIPOR1 SNPs associated with insulin levels and genotype differences were more often 
seen in men (Figure 11). The T allele of rs10920534 and the C allele of rs12045862 associated 
with higher two-hour insulin levels in men (p=0.027 and p=0.001, respectively, for comparison 
among three genotype groups, adjusted for age and BMI), but women carrying the rs12045862 T 
allele had higher two-hour insulin levels (p=0.029). Moreover, rs12045862 C allele and rs7539542 
C allele associated with higher fasting serum insulin in men (p<0.001 and p=0.001, respectively). 
None of the ADIPOR1 SNPs analysed predicted conversion from IGT to T2DM. 
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Figure 11. Baseline fasting and two-hour insulin according to ADIPOR1 rs10920534 (A and D), rs12045862 (B 
and E), and rs7539542 (C and F) in men participating DPS (Study III). Data are mean±SEM. ANOVA across all 
three genotypes were adjusted for age and BMI.  
5.4.5 ADIPOR2 SNPs and the risk of T2DM (Study IV)
The  rare  minor  alleles  of  two  ADIPOR2 SNPs  associated  with  the  risk  of  T2DM.  Subjects  
homozygous for the rs11061946 T allele and the rs11061973 A allele (n=5) had significantly 
higher risk of T2DM compared with subjects homozygous for the major alleles (Table 8). When 
study groups were analyzed separately, results were similar in both study groups.  
5.5 ASSOCIATION OF ADIPOR2 VARIANTS WITH CVD (STUDY IV)
After a median follow-up period of 10.2 years, there were 100 CVD events among the DPS 
participants who were available for genetic analyses (50/241 in the intervention and 50/232 in 
the control group) (363). Four ADIPOR2 SNPs  were  associated  significantly  with  the  risk  of  
CVD (Figure 12). The rs10848554 C allele associated with an increased risk of CVD when 
compared with the GG genotype (HR=1.61, 95% CI: 1.04-2.50, p=0.032/q=0.085). Additionally, 
carriers of the rs11061937 C allele had significantly lower risk of a CVD event than those with 
the TT genotype (HR=0.59, 95% CI: 0.39-0.88, p=0.019/q=0.085). Finally, the rs1058322 T allele 
and the rs16928751 A allele were dose-dependently associated with higher risk of CVD 
(HR=1.75, 95% CI: 1.14-2.68, p=0.010/q=0.085 and HR=1.80, 95% CI: 1.12-2.82, p=0.010/q=0.085 for 
dominant inheritance models, respectively). The analyses were performed separately in the 
intervention  and  in  the  control  group,  and  similar  results  were  found  in  both.  Moreover,  no  
significant interaction between ADIPOR2 variants  and  sex  or  baseline  BMI  on  CVD  risk  was  
found.  In  the  multiple  SNP  model,  including  all  four  SNPs,  two  variants  (rs11061937  and  
rs1058322) remained significant predictors of CVD risk (p=0.014 and p=0.020, respectively). 
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Figure 12. Cox survival curves for CVD incidence according to ADIPOR2 rs10848554 (A), rs11061937 (B), 
rs1058322 (C), and rs16928751 (D) in DPS participants (Study IV). Dominant inheritance model, adjusted for 
age, sex, baseline BMI, study group, CVD at baseline, systolic blood pressure, smoking status, and baseline 
total-to-HDL cholesterol ratio.  
5.6 ALLELE DIFFERENCES IN THE MRNA EXPRESSION OF ADIPOR2
(STUDY IV)
In the PBMCs, the expression of the ADIPOR2 at the mRNA level differed according to the 
rs1058322 genotype (p=0.029/q=0.328 adjusted for age, sex and baseline BMI) with individuals 
carrying  the  T  allele  demonstrating  lower  expression  levels  than  those  with  the  CC  genotype  
(Study IV: Figure 2 B). A trend for dose-dependent effect was seen when using the additive 
inheritance analysis model (p=0.091/q=0.328). None of the other SNPs included in the present 
study associated with the mRNA expression levels in PBMCs, and no differences in expression 
levels according to ADIPOR2 SNPs were seen in AT samples.  
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6 Discussion
6.1 METHODOLOGICAL ISSUES 
6.1.1 Study population 
The major strength of this study series is the use of clinically well-defined and carefully selected 
study populations. The DPS population is a homogeneous group of overweight and middle-
aged Finnish individuals  with  IGT who are  at  high risk  of  developing T2DM and CVD (129).  
Likewise, the participants of the Genobin study (Study IV) were overweight and middle-aged 
Finnish individuals  with  either  IGT or  IFG and additional  features  of  metabolic  syndrome.  In  
the DPS, the prospective study design and longitudinal follow-up data are superior to case-
control or cross-sectional samples, which are typically used in candidate gene studies (374). 
Another advantage is that, compared with more admixed populations of central European 
background,  the  Finnish  population  is  characterised  by  relatively  low  genetic  diversity  and  a  
high  degree  of  LD.  This  genetic  homogeneity  may  offer  benefits  in  performing  genetic  
association studies,  even though some caution for  population substructures  may be  necessary 
(375, 376). The genetic homogeneity of the Finnish population is due to the demographic history 
of Finland, which is characterised by a small founder population, long-standing isolation, 
several population bottlenecks and recent expansion (377).  
The main limitation of the study populations used was the moderate sample size of the DPS 
and the small sample size of the Genobin population. This may weaken the statistical power to 
find true associations and increase the chance of false positive findings, particularly in the case 
of gene variants with low MAF. Moreover, in two studies only a subset of the DPS participants 
was used for genetic association analyses: in Study I, the FSIGT was performed at baseline for 83 
individuals, and in Study II the baseline serum adiponectin levels were measured from 243 
individuals, further decreasing the statistical power. The Genobin study was originally 
designed as a clinical intervention study and the number of participants may be considered too 
small for genetic studies. However, allele-specific differences could be detected in the mRNA 
expression levels that were biologically plausible and may be considered statistically significant. 
6.1.2 Candidate gene approach 
Generally, the results of genetic association studies of complex diseases have proven difficult to 
replicate. Several explanations may underlie the inconsistent results. First, the allele frequencies 
and LD patterns vary between populations with different ethnic backgrounds. Another reason 
is that multiple environmental and genetic factors, and their interactions, affect quantitative 
traits and the risk of complex diseases, such as obesity and T2DM. Furthermore, the effect sizes 
of individual variants are usually small, and different combinations of predisposing and 
protective variants may lead to various outcomes. In addition, direct comparison of individual 
studies is challenging, since different combinations of SNPs are usually investigated in each 
study.  
During the past decade, the nature of genetic association studies has changed dramatically 
due to technological development, and decreasing costs of genotyping and sequencing. 
Nowadays GWASs dominate the field and significantly larger study populations are required 
for sufficient statistical power. However, as GWASs have certain limitations, candidate gene 
studies performed with carefully selected candidate genes in high-quality study populations 
still hold their value, especially when the results are replicated in independent study 
populations. Moreover, the candidate gene approach is likely to be used in the future for more 
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accurate localisation of true functional variant(s) after an association between genomic region 
and phenotype is revealed by GWAS (61). 
6.1.3 Candidate gene and SNP selection 
Candidate genes in these studies were selected based on previous literature and the biological 
information available on gene products and their functions in metabolic processes.  
In early candidate gene studies typically only one or few markers, often known or suspected 
to be functional, per gene were genotyped. However, the international HapMap project (13) has 
yielded information on LD patterns  in  different  human populations  and it  is  now possible  to  
select minimal set of tagSNPS to capture most of the genetic variation in a given region.  
This general trend of the field is reflected in this series of studies. Study I may be regarded as 
a candidate polymorphism study, since a single functional variant was genotyped, whereas in 
Studies II-III, a set of tagSNPs was selected to cover the maximal amount of common variation 
in the candidate gene loci. 
6.1.4 Genotyping accuracy  
The genotyping methods used in Studies I-IV vary according to the technological development 
in the field. In each study, an appropriate number of samples were replicated in order to 
confirm genotyping accuracy. Moreover, as a genotyping quality check, each variant was tested 
for HWE. A significant deviation from HWE may indicate genotyping error, but may also result 
from population stratification, non-random mating, selection, inbreeding or presence of 
common deletion polymorphisms (378). The genotype frequencies of two SNPs, the ADIPOQ
rs16861210 and the ADIPOR2 rs11061946, deviated from HWE at a significance level of p<0.050. 
However, the FDR for both was high (q>0.150), and therefore both SNPs were included in 
subsequent analyses. It is likely that the violation of HWE is due to change, as is often the case 
for variants with low genotype counts (378). In addition, it is noteworthy that the HWE should 
always be tested in a control population, since deviation may actually be an indication of 
disease association (379). 
6.1.5 Statistical issues 
Performing multiple statistical tests in genetic association studies is a common problem and it 
increases the probability of false positive results. A general practice for applying correction for 
multiple comparisons is lacking, and the available correction methods are generally not well 
suited for hypothesis-driven candidate gene approach. In the context of correlated tests, such as 
testing multiple SNPs that are in LD, or related phenotypes, the conservative Bonferroni 
method, in which p-values are multiplied by total number of tests, may lead to rejection of true 
associations in studies with limited power (57, 378). Therefore, replication of the associations in 
independent study populations is considered to be the optimal way to separate genuine 
associations from false positives (380). 
In these studies, the unadjusted p-values were considered cautiously with the significance 
level at p<0.05. Additionally, in Studies II and IV the FDR method, which estimates the 
proportion of false positive tests among all positives, was used for correction of multiple 
comparisons. The FDR derived q-values were considered together with the p-value in these 
studies. A result with p-value below the traditional =0.05 level, but with high q-value might be 
expected to be a false positive finding. Since a common threshold for q-value has not been 
established, the exact q-values are reported and those below 0.150 are considered suggestive of 
a true association. 
In Study I, the association of the ADRA2B variant with the T2DM incidence was analysed by 
logistic regression after three years of follow-up. However, in subsequent studies the follow-up 
was extended to seven years and the conversion from IGT to T2DM was analysed by Cox 
regression analysis, which takes into account the survival time until the development of T2DM 
and  is  capable  of  handling  information  regarding  individuals  who  dropped  out  of  the  study.  
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Similarly, in Study III, the longitudinal analyses were performed with the three-year follow-up 
data using the GLM repeated measures procedure, whereas in Study II, the longitudinal data 
during four  years  of  follow-up were  analysed using linear  mixed models  analysis,  which can 
take into account subjects with missing data. In this thesis, the data from Studies I and III were 
re-analysed using same follow-up duration and statistical methods that were used in later 
studies and the results remained essentially similar to the original studies. 
6.2 CONSIDERATION OF MAJOR RESULTS 
6.2.1 Association studies on ADRA2B gene  
The results of Study I suggest that the ADRA2B 12Glu9 variant is associated with AIR and DI, 
the markers of beta cell function, in individuals with IGT. The Glu9 allele associated with lower 
AIR and DI, but also with a higher risk of T2DM in individuals who had high WC or were not 
included in the lifestyle intervention group of the DPS. In contrast, the risk of T2DM risk may 
be slightly decreased, in individuals carrying the Glu9, who were involved in the lifestyle 
intervention or who had low WC.  
As  a  product  of  insulin  sensitivity  and  first  phase  insulin  secretion  measures,  DI  describes  
the ability of beta cells to compensate for decreased insulin sensitivity by increasing insulin 
secretion (132, 136). It can be assumed that the capacity of beta cells to compensate for insulin 
resistance is already disturbed to some extent in participants of the DPS who all had IGT. 
Nevertheless, the Glu9 allele was dose-dependently associated with lower DI and similar 
genotype difference was seen in insulin secretory capacity (AIR), even when not adjusting for 
insulin sensitivity. Finally, indicating impaired beta cell function, the normal exponential 
relationship between AIR and SI was absent in carriers of the Glu9 allele.  
Measures of insulin secretion have been shown to have high heritability (381), and most of 
the genetic variants associated with T2DM identified so far are related to insulin secretion 
rather than to insulin sensitivity of target tissues (160, 189, 382). This study was the first to 
report the association between ADRA2B 12Glu9 with beta cell function, AIR and risk of T2DM. 
The observation is strengthened by the observation that the association with the risk of 
conversion  from  IGT  to  T2DM  remained  significant  in  the  whole  study  population  and  in  
individuals with high WC after the extended follow-up time.  
The 12Glu9 variant involves three glutamic acid residues in the third intracellular loop of the 
2B-AR (343). The deletion allele has been shown to have functional consequences by impairing 
the agonist-promoted receptor desensitisation in vitro (343). Since complex neural mechanisms 
are involved in the regulation of insulin secretion (341) and blockage of 2-ARs has been shown 
to improve glucose-potentiated insulin secretion in T2DM (383), it may be hypothesised that the 
Glu9 allele might cause prolonged inhibition of insulin secretion through impaired receptor 
desensitisation.  
The Glu9 allele was not a significant predictor of T2DM in individuals who were involved in 
lifestyle intervention or who were less abdominally obese. Compared with individuals in the 
control group, those in the intervention group achieved significantly larger weight loss leading 
to improvement in insulin sensitivity (362, 368). These results suggest that the improvement in 
insulin sensitivity, due to beneficial lifestyle changes, benefits more the carriers of the Glu9 
allele, whose beta cell capacity may be genetically impaired. Similarly, central obesity is 
connected to insulin resistance (132), and the Glu9 allele increased the risk of T2DM only in 
individuals with high WC. This interactive effect of 12Glu9 with baseline WC was still 
detectable after the extended follow-up time. Interestingly, others have also reported similar 
interactions between 12Glu9 and lifestyle (358-360). 
Up until the time of writing, the association with beta cell function has not been replicated. 
Furthermore, ADRA2B SNPs has  not  been identified by GWAS for  T2DM or  traits  relating to  
beta cell capacity (70). However, Papazoglou et al. (384) reported that among individuals with 
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T2DM, the Glu9 allele associated with earlier onset of T2DM and a variant in the gene encoding 
the 2A-AR subtype was recently implicated in insulin secretion and the risk of T2DM (385, 
386).
6.2.2 Association studies on ADIPOQ gene 
Several SNPs in the ADIPOQ locus were associated with body weight, the risk of T2DM, and 
serum  adiponectin  concentrations  in  the  participants  of  the  DPS  study.  These  results  lend  
support to the role of ADIPOQ variations in conditions linked to T2DM and obesity, by 
replicating earlier findings, but also presenting novel associations. Another aim of Study II was 
to examine whether ADIPOQ SNPs modify the effect of lifestyle intervention on various 
metabolic traits. Gene-lifestyle interactions were not found, however, and the results were 
basically similar when the study groups were analysed separately. 
The studies investigating association of ADIPOQ variants with metabolic traits have given 
highly inconsistent results in various study populations. The strongest and most consistent 
evidence exists for association of ADIPOQ variants with circulating adiponectin levels (203, 237, 
240, 241, 298, 299, 305, 308, 309, 387) supporting the strong genetic control of adiponectin. On 
the contrary, the role of ADIPOQ variants in obesity and T2DM is more controversial (218). At 
the time of the writing of this thesis, five GWAS on circulating adiponectin have been reported 
in the NHGRI Catalogue of Published Genome-Wide Association Studies and four of these have 
identified the ADIPOQ locus  with  genome-wide  significance  (70).  By  contrast,  none  of  the  
GWAS for T2DM or obesity have identified ADIPOQ variants.  
In the DPS population, the C allele of the promoter variant rs266729 was associated with an 
increased risk of T2DM, whereas the G allele associated with body weight particularly in 
women. Others have also reported an association between rs266729 and obesity-related 
phenotypes (305, 309), the risk of T2DM (388), or insulin resistance (305, 318), but mostly with 
opposing risk alleles. In accordance with the results of the present study, the C allele associated 
with an increased risk of T2DM in a German study population (310) and lower insulin 
sensitivity in a cohort of Caucasian adolescents and their parents (312). Although associations 
between circulating adiponectin levels and rs266729 and other promoter SNPs have been 
reported widely (240, 241, 299, 308, 309), an association between rs266729 and adiponectin 
levels was not found in the DPS, possibly due to lack of statistical power. It is currently unclear 
whether rs266729 has any functional relevance or is in LD with a yet unidentified functional 
variant(s). A recent functional study suggested that rs266729 may alter the binding site of 
transcriptional stimulatory protein (389). Another study reported that rs266729 and two other 
promoter SNPs have an important role in regulating ADIPOQ promoter activity (313). On the 
other hand, results of three other functional studies suggest that rs266729 does not directly 
influence the transcription efficiency (240, 305). Two studies have found that the effect of this 
variant may also be sensitive to dietary factors (318, 390). Santos et al. (390) found an interactive 
effect of rs266729 and the percentage of energy derived from fat on obesity, whereas in another 
study interactive effect with plasma levels of saturated fatty acids was found on homeostasis 
model assessment of HOMA-IR (318). 
Rs16861205 was associated with body weight at baseline and during the four-year follow-up 
in the DPS. The association between body weight and rs16861205 has not been reported 
previously, and this intronic SNP does not have any obvious functional role. These observations 
are therefore likely explained by LD with another variant of functional significance.  
Rs16861210 and rs17366568 associated strongly with baseline serum adiponectin levels in a 
subgroup of the DPS participants. Although both SNPs are located in intron 1, they are not in 
LD with each other and probably represent independent genetic signals. Neither rs16861210 nor 
rs17366568 have any known functional role, but three SNPs located immediately on either side 
of rs17366568 were recently predicted to affect transcription factor binding sites (243). Previous 
studies have not examined the association between rs16861210 and adiponectin levels. 
However, consistent with the results of the present study, the A allele of rs17366568 associated 
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with lower adiponectin levels in white, but not black women (316). Moreover, a recent GWAS 
found that rs17366568 explained 3.8% of variation in adiponectin levels, while altogether 6.7% 
of the variation was explained by at least nine independent SNP groups in the ADIPOQ locus 
(243).
Rs2241766 is one of the most extensively studied ADIPOQ SNPs.  It  a  synonymous  SNP  
located in the exon 2, and is in strong LD with rs2082940, which is located in the 3’UTR region. 
Both rs2241766 and rs2082940 have low MAF and the only two individuals in the DPS who 
were homozygous for the rs2241766 minor allele were also homozygous for the rs2082940 
minor allele and vice versa. The results were basically identical for these two SNPs: the minor 
alleles  (G  and  T,  respectively)  associated  with  a  higher  risk  of  T2DM,  but  paradoxically  with  
higher adiponectin levels, particularly in men. Although the association between the rs2241766 
G allele and T2DM related traits (66, 291, 292, 300) and between the T allele and low adiponectin 
levels (298, 299, 387) have also been reported by others, these contradictory results should be 
interpreted with caution due to the low MAFs of these SNPs.  
Rs1501299 is another commonly studied ADIPOQ SNP  with  an  unknown  functional  role.  
Consistent with the observed association between rs1501299 and body weight in the DPS 
population, a number of earlier studies have reported association with obesity-related traits 
(298, 305). The results are, however, conflicting as the risk allele varies among populations, and 
some studies have failed to replicate these findings (307).  
The strongest association for body weight in the DPS was found for rs3821799. The genotype 
differences  in  weight  remained  significant  during  the  four-year  follow-up  regardless  of  the  
study group. Moreover, rs3821799 remained significant predictor of baseline body weight in a 
multi  SNP  model  with  all  the  SNPs  associating  with  body  weight.  This  SNP  is  intronic,  its  
possible functional role is not known, and it has not been examined in previous association 
studies have.  
The rs6773957 G allele associated with both high body weight and low serum adiponectin 
levels in the DPS participants. Association of this SNP with body weight has not been reported 
in earlier studies, but in a recent genome-wide linkage and association scan rs6773957, and 
another SNP in LD with it, were found to be strongly associated with adiponectin levels (237). 
Furthermore, two recent studies have reported an association between the rs6773957 G allele 
and low circulating adiponectin levels (203, 241). The functional role of this variant is currently 
unknown, but given the consistent results seen in various study populations and the location of 
this  SNP  in  the  3’UTR,  where  it  may  have  an  effect  on  mRNA  stability  or  translational  
efficiency, future studies are warranted.  
In conclusion, the results of Study II supported the well established role of ADIPOQ SNPs in 
explaining the variation in circulating adiponectin levels, but also a more contradictory role in 
other traits related to T2DM and obesity.  
6.2.3 Association studies on ADIPOR1 gene 
In Study III, consistent and significant association between ADIPOR1 SNPs  and  various  body  
size measures were found. Moreover, three ADIPOR1 SNPs associated with fasting and post-
challenge  insulin  levels  with  sex-specific  differences,  but  none  of  the  SNPs  examined  were  
associated with T2DM risk.  
Several earlier association studies have focused on ADIPOR1 variants reporting associations 
with various traits including insulin resistance (302, 312, 318, 320, 326, 332), high liver fat (332), 
and obesity or fat distribution (306, 306, 318, 330). Few studies have found association between 
ADIPOR1 variations and T2DM (324, 333), but similar to the results of Study III most have 
reported negative results (321, 325, 331, 334, 335). On the other hand, whereas in this and a few 
other studies (318, 330) significant associations between ADIPOR1 variants and several body 
size measurements were found, others have failed to detect such associations (316, 321, 325, 
333). Overall, the results are inconsistent, and some studies have suggested that factors such as 
ethnicity (312), obesity status (326, 391) or genetic background (306) may influence the effect of 
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these variants and, thus explain the discrepancies. The results of Study III suggest that the 
influence of ADIPOR1 variants on body size and insulin levels may depend on sex, but Collins 
et al. (325) were unable to be find evidence for such interactive effect in a large population-based 
study. Other possible explanations for contradictory results include differences in study design 
or in allele frequencies and LD patterns between populations.  
More specifically, three SNPs (rs10920534, rs2275738 and rs1342387) were associated with 
various body size measurements at baseline and with WC and body weight during the three-
year follow-up. None of these variants have any known functional role and so far these results 
have not been replicated in other populations. Rs6666089 is located in the ADIPOR1 promoter 
region and is in complete LD with an intronic SNP rs10920534 in DPS. Rs6666089 has been 
included  in  several  association  studies,  but  did  not  associate  with  BMI  or  other  body  size  
measurements (316, 321, 330, 333). Likewise rs2275738 and rs2275737, which are in complete 
LD, and the intronic variant rs1342387 have been associated with body size measures in other 
populations (316, 325, 330, 333). These three SNPs are in moderate to high LD with each other 
(Study II, Table 1: r2=0.264-0.849 and D’=0.996-1.0) and may be merely markers of a true 
functional variant(s) in ADIPOR1 or nearby loci. 
In the DPS, rs10920534, rs12045862 and rs7539542 demonstrated sex-specific associations 
with baseline fasting and 2-h insulin levels. Rs10920534 was associated with the baseline two-
hour glucose levels in men. Collins et al. (325) did not find association between rs6666089 
(which is in complete LD with rs10920534) and insulin levels, but this SNP associated with 
insulin resistance with adiposity dependent manner in another study population (391). 
Intriguingly, different alleles of rs12045862 associated with high insulin levels in men and 
women.  The  functional  role  of  this  intronic  SNP  is  not  known  and  the  results  of  the  present  
study are not supported by other association studies (325). Therefore, the sex-specific effect of 
this variant remains inconclusive.  
Rs7539542 is located in the 3’UTR and has been associated with body size measurements 
(330) and insulin resistance (312) in other populations, but was not associated with fasting or 
two-hour insulin levels in large population based study (325). In future, the association of 
ADIPOR1 variants with insulin levels, and the observed differences between men and women, 
needs to be investigated in larger study populations.  
Interestingly, a strong association between ADIPOR1 variants and height was observed in 
the female participants of the DPS. Height is a complex trait with heritability estimates ranging 
from 0.68 to 0.84 (392). Currently, genetic variants in at least 180 loci are known to influence 
adult height (393). The mechanistic link between adiponectin pathway and adult height is 
unknown, but birth length and circulating adiponectin levels do correlate positively (217).  
In summary, ADIPOR1 variants were associated with body size, fat distribution and insulin 
levels in individuals with IGT. The observed associations differed between men and women. 
The mechanism of these sex-specific differences is unknown, but may be related to the well 
documented sexual dimorphism in circulating adiponectin levels (201, 216). 
6.2.4 Association studies on ADIPOR2 gene 
In Study IV, a significant association between four ADIPOR2 SNPs (rs10848554, rs11061937, 
rs1058322 and rs16928751) and the risk of CVD was found. When all four SNPs were included 
in the same model only rs11061937 and rs1058322 remained significant predictors of CVD risk, 
indicating independent effects of these two variants. This view is supported by the observation 
that rs11061937 was in low LD (r2 ranging from 0.0090 to 0.071) with the other three SNPs, 
whereas rs1058322 was in moderate LD with rs10848554 and rs16928751, and rs10848554 and 
rs16928751 were in high LD with each other (Study IV: Table 3). In addition, two ADIPOR2
SNPs (rs11061946 and rs11061973) associated with the risk of T2DM. Individuals (n=5) 
homozygous for the minor alleles of these two SNPs had a higher risk of converting from IGT to 
T2DM.  
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Several studies have investigated the association of ADIPOR2 variants with traits relates to 
T2DM or CVD risk, but the results are somewhat inconsistent, and only a few studies have 
included the same SNPs that were genotyped in DPS. Earlier studies have reported associations 
between ADIPOR2 SNPs and plasma TG concentrations (319, 327, 328, 330), and T2DM 
incidence or related traits (312, 322, 327, 331, 333). On the other hand, a number of studies have 
failed to replicate association with T2DM (320, 321, 324, 325, 334) and insulin resistance (318, 
332).
More specifically, the rs16928751 variant has been previously associated with fasting TG 
levels in a small study population of individuals with metabolic syndrome (328), and T2DM in 
a case-control study (322). Rs1044471, located in the 3’ UTR, was associated with T2DM in an 
Amish population (333), but not in the DPS or in a Korean case-control population (320). 
Probably the most extensively studied ADIPOR2 SNP is an intronic variant rs767870, which 
was associated with CAD, intima media thickness and endothelial function in a cross-sectional 
study population (317). Moreover it was associated with fasting plasma TG concentrations in 
Mexican-American subjects (330), and in a population based sample of 3050 Finnish subjects 
(319). Rs767870 has also been associated with measures of liver fat content and its surrogate 
markers (319), and T2DM in a case-control study of 1498 Caucasian subjects (331). 
Unfortunately, rs767870 was not genotyped in the present study. However, three of the SNPs 
that associated with CVD risk in the DPS are in moderate or high LD with rs767870 in the 
HapMap CEU population (394) potentially capturing the same genetic information (rs10848554: 
r2=0.774 and D’=0.916, rs1058322: r2=0.337 and D’=0.895, and rs16928751: r2=0.838 and D’=1.0). 
Importantly, rs767870 is not in high LD with rs11061937 (r2=0.073 and D’=1.0) or the two T2DM
associated SNPs rs11061946 (r2=0.014 and D’=1.0) and rs11061973 (r2=0.036 and D’=1.0), which 
therefore likely represent independent genetic signals.  
ADIPOR1 and ADIPOR2 expression may be regulated in a tissue specific manner and may be 
influenced by genetic factors. At the moment, however, the regulatory mechanisms at mRNA 
and protein levels are poorly understood, and the results of different studies are contradictory. 
Halvatsiotis et al. (317) observed that the A allele of the rs767870 was associated with higher 
levels of ADIPOR2 protein expression in peripheral monocytes. Interestingly, in the present 
study differences in ADIPOR2 mRNA expression levels were seen according to the rs1058322 
genotype in PBMCs derived from individuals with metabolic syndrome. Individuals carrying 
the T allele, who had an increased risk of CVD in the DPS population, demonstrated decreased 
mRNA expression. The PBMCs are important factors in inflammation, which is closely 
connected to both CVD and T2DM (395). Moreover, monocytes and macrophages are the target 
cells of the antiatherogenic and anti-inflammatory effects of adiponectin (283) and SNPs 
affecting ADIPOR2 expression tissue-specifically may disturb these interactions directly. The 
mechanisms by which ADIPOR2 variants might influence the regulation gene expression or the 
risk of CVD and especially T2DM are currently hypothetical. The potential role of rs1058322, 
located in intron 1, in the tissue-specific regulation of gene expression is currently unknown. It 
may instead be a marker in LD with yet uncharacterised functional variant(s).  
In conclusion, the results of Study IV are in agreement with previous findings suggesting a 
role for ADIPOR2 gene  in  susceptibility  to  CVD  and  T2DM,  possibly  through  independent  
genetic effects. Different variants in the ADIPOR2 locus may act independently or in concert to 
induce subtle, and possibly tissue specific, alterations in gene expression. The observation of 
allele-specific differences according to rs1058322 variant in mRNA expression levels further 
support this view.
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6.3 FUTURE PERSPECTIVES 
Over the past years, the understanding of the genetics of several complex diseases and traits has 
increased dramatically. The research has shifted from candidate gene studies to GWAS, and 
towards using ever larger study populations.  
The rationale for investigating the genetic component of complex diseases and traits, such as 
T2DM, CVD and obesity, is obvious. The prevalence of obesity has increased rapidly over the 
past decades and it is associated with severe co-morbidities, such as T2DM, CVD, which are the 
leading causes of morbidity and mortality worldwide, and account for large part of the financial 
burden on the health care system (396).  
Despite advances, a significant portion of the heritability of complex obesity-related traits 
remains to be identified. In the near future, the search for the heritable component will be 
extended to rare variants, CNVs, the epigenome modifications and interactions between genetic 
and non-genetic factors. The next-generation sequencing methods will soon enable sequencing 
of whole genomes, which in turn will facilitate identifying inter-individual differences genetic 
predisposition to complex diseases. It is likely that significant genetic heterogeneity underlies 
complex conditions and therefore classification to new disease subcategories may become 
necessary.  
The prediction of disease risk based on genetic factors has proven limited, and perhaps not 
applicable to clinical practice, due to strong non-genetic influences and the fact that a large 
number of variants with moderate effect sizes are involved with most individuals carrying both 
risk and protective alleles (397). However, knowing one’s genetic risk may be an important 
factor motivating towards healthier lifestyle choices. In fact some studies have suggested that a 
genetic  risk  score  may  improve  prediction  in  younger  individuals  for  whom  medical  and  
lifestyle interventions may be most beneficial (398). 
The most important aspect of recognizing genetic variants associating with complex diseases 
is, however, the recognition of novel etiological pathways and biological processes involved in 
disease pathogenesis, which will lead to more accurate precision of the disease subtype and 
serve as targets for future preventive and therapeutic strategies (6, 56).  
It is also worth noting that the information on environmental exposures relating to complex 
traits and diseases is often incomplete and non-systematic. Another less obvious advantage of 
identifying new genetic variants associating with complex traits is that when new molecular 
pathways to various diseases are recognised, they will also give clues of crucial environmental 
exposures relating to each disease (399). 
6.4 SUMMARY AND CONCLUDING REMARKS 
In Study I an association between the functional ADRA2B gene 12Glu9 variant and AIR and DI 
was found in a DPS subpopulation. The risk allele of this variant also associated with an 
increased  risk  of  converting  from  IGT  to  T2DM  in  the  whole  DPS  population,  particularly  in  
individuals with central obesity. These results appear biologically plausible, given that 2-ARs
regulate many physiological functions in various tissues, including insulin secretion in beta 
cells, and this variant leads to impaired receptor function. However, this finding has not been 
replicated in later association studies. Therefore, it has to be concluded that the role of the 
ADRA2B 12Glu9 variant in beta cell function and the risk for T2DM remains unclear. In this 
regard, studies on rare genetic variants may yield additional information. 
Studies II-IV concentrated on the role of genes in the adiponectin pathway in various 
metabolic outcomes. Convincing evidence indicates that decreased levels of circulation 
adiponectin are associated with several adverse metabolic conditions. Moreover, it has been 
clearly demonstrated that adiponectin has direct insulin-sensitising, anti-atherogenic and anti-
inflammatory effects. The genetic component of circulation adiponectin levels is strong and at 
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this point it is clear that ADIPOQ gene variants contribute significantly to adiponectin levels, 
even though the mechanisms remain unsolved. In Study II five ADIPOQ variants associated 
with serum adiponectin levels. It is unclear whether any of these variants have functional 
effects, but the present study, as well as several earlier studies, suggests that more than one 
variant affecting circulating adiponectin levels exist in the ADIPOQ locus. The association of 
ADIPOQ variants with other metabolic traits remains unclear and may be population specific.  
The role of ADIPOR1 and ADIPOR2 gene variants in body size and various metabolic traits 
and disease risk is even less clear as the results vary across study populations. In Study III 
associations between ADIPOR1 SNPs and various body size measures were found. In addition, 
ADIPOR1 SNPs associated with insulin levels in men. Some later studies have reported similar 
results, whereas in others the results have been negative. ADIPOR1 variants with effects on 
gene expression or on receptor function remain to be identified.  
In Study IV, an association between ADIPOR2 variants and the risk of CVD was found, and 
the results were supported by tissue and allele-specific differences in the mRNA expression 
levels. These results are in accordance with a few other association studies investigating 
ADIPOR2. Nevertheless, the possible effect of rs1058322 on gene expression needs to be 
investigated in larger study populations and at the protein level.  
Lastly, an important aim of this series of studies was to investigate the possible gene-lifestyle 
interactions. In Study I, the role of lifestyle x ADRA2B gene variant interaction was significant, 
but for the adiponectin pathway genes, the response to lifestyle was essentially similar 
regardless of genotype. 
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The present study utilised a candidate 
gene approach to identify gene vari-
ants associated with type 2 diabetes, 
obesity and related traits in individu-
als with impaired glucose tolerance. 
The candidate genes included in the 
present study, ADRA2B, ADIPOQ, 
ADIPOR1 and ADIPOR2, were select-
ed based on biological plausibility and 
the previous literature. The results of 
this thesis suggest that genetic differ-
ences in susceptibility to obesity and 
its comorbidities may exist. Moreover, 
individuals with different genotypes 
may respond differently to beneficial 
lifestyle changes.
 
